<!DOCTYPE html>

<html lang="en" xml:lang="en">

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />

<meta name="viewport" content="width=device-width, initial-scale=1" />



<title>replicateBE</title>

<script>// Pandoc 2.9 adds attributes on both header and div. We remove the former (to
// be compatible with the behavior of Pandoc < 2.8).
document.addEventListener('DOMContentLoaded', function(e) {
  var hs = document.querySelectorAll("div.section[class*='level'] > :first-child");
  var i, h, a;
  for (i = 0; i < hs.length; i++) {
    h = hs[i];
    if (!/^h[1-6]$/i.test(h.tagName)) continue;  // it should be a header h1-h6
    a = h.attributes;
    while (a.length > 0) h.removeAttribute(a[0].name);
  }
});
</script>

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>



<style type="text/css">
  code {
    white-space: pre;
  }
  .sourceCode {
    overflow: visible;
  }
</style>
<style type="text/css" data-origin="pandoc">
pre > code.sourceCode { white-space: pre; position: relative; }
pre > code.sourceCode > span { display: inline-block; line-height: 1.25; }
pre > code.sourceCode > span:empty { height: 1.2em; }
.sourceCode { overflow: visible; }
code.sourceCode > span { color: inherit; text-decoration: inherit; }
div.sourceCode { margin: 1em 0; }
pre.sourceCode { margin: 0; }
@media screen {
div.sourceCode { overflow: auto; }
}
@media print {
pre > code.sourceCode { white-space: pre-wrap; }
pre > code.sourceCode > span { text-indent: -5em; padding-left: 5em; }
}
pre.numberSource code
  { counter-reset: source-line 0; }
pre.numberSource code > span
  { position: relative; left: -4em; counter-increment: source-line; }
pre.numberSource code > span > a:first-child::before
  { content: counter(source-line);
    position: relative; left: -1em; text-align: right; vertical-align: baseline;
    border: none; display: inline-block;
    -webkit-touch-callout: none; -webkit-user-select: none;
    -khtml-user-select: none; -moz-user-select: none;
    -ms-user-select: none; user-select: none;
    padding: 0 4px; width: 4em;
    color: #aaaaaa;
  }
pre.numberSource { margin-left: 3em; border-left: 1px solid #aaaaaa;  padding-left: 4px; }
div.sourceCode
  {   }
@media screen {
pre > code.sourceCode > span > a:first-child::before { text-decoration: underline; }
}
code span.al { color: #ff0000; font-weight: bold; } /* Alert */
code span.an { color: #60a0b0; font-weight: bold; font-style: italic; } /* Annotation */
code span.at { color: #7d9029; } /* Attribute */
code span.bn { color: #40a070; } /* BaseN */
code span.bu { } /* BuiltIn */
code span.cf { color: #007020; font-weight: bold; } /* ControlFlow */
code span.ch { color: #4070a0; } /* Char */
code span.cn { color: #880000; } /* Constant */
code span.co { color: #60a0b0; font-style: italic; } /* Comment */
code span.cv { color: #60a0b0; font-weight: bold; font-style: italic; } /* CommentVar */
code span.do { color: #ba2121; font-style: italic; } /* Documentation */
code span.dt { color: #902000; } /* DataType */
code span.dv { color: #40a070; } /* DecVal */
code span.er { color: #ff0000; font-weight: bold; } /* Error */
code span.ex { } /* Extension */
code span.fl { color: #40a070; } /* Float */
code span.fu { color: #06287e; } /* Function */
code span.im { } /* Import */
code span.in { color: #60a0b0; font-weight: bold; font-style: italic; } /* Information */
code span.kw { color: #007020; font-weight: bold; } /* Keyword */
code span.op { color: #666666; } /* Operator */
code span.ot { color: #007020; } /* Other */
code span.pp { color: #bc7a00; } /* Preprocessor */
code span.sc { color: #4070a0; } /* SpecialChar */
code span.ss { color: #bb6688; } /* SpecialString */
code span.st { color: #4070a0; } /* String */
code span.va { color: #19177c; } /* Variable */
code span.vs { color: #4070a0; } /* VerbatimString */
code span.wa { color: #60a0b0; font-weight: bold; font-style: italic; } /* Warning */

</style>
<script>
// apply pandoc div.sourceCode style to pre.sourceCode instead
(function() {
  var sheets = document.styleSheets;
  for (var i = 0; i < sheets.length; i++) {
    if (sheets[i].ownerNode.dataset["origin"] !== "pandoc") continue;
    try { var rules = sheets[i].cssRules; } catch (e) { continue; }
    for (var j = 0; j < rules.length; j++) {
      var rule = rules[j];
      // check if there is a div.sourceCode rule
      if (rule.type !== rule.STYLE_RULE || rule.selectorText !== "div.sourceCode") continue;
      var style = rule.style.cssText;
      // check if color or background-color is set
      if (rule.style.color === '' && rule.style.backgroundColor === '') continue;
      // replace div.sourceCode by a pre.sourceCode rule
      sheets[i].deleteRule(j);
      sheets[i].insertRule('pre.sourceCode{' + style + '}', j);
    }
  }
})();
</script>




<style type="text/css">body{background-color:#fff;margin:1em auto;max-width:700px;overflow:visible;padding-left:2em;padding-right:2em;font-family:"Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif;font-size:14px;line-height:1.35;hyphens:auto}#header{text-align:center}#TOC{clear:both;margin:0 0 10px 10px;padding:4px;width:400px;border:1px solid #CCC;border-radius:5px;background-color:#f6f6f6;font-size:13px;line-height:1.2em}#TOC .toctitle{font-weight:bold;font-size:15px;margin-left:5px}#TOC ul{padding-left:40px;margin-left:-1.5em;margin-top:5px;margin-bottom:5px}#TOC ul ul{margin-left:-2em}#TOC li{list-style-type:none;line-height:16px}table{margin:1em auto;border-width:1px;border-color:#DDD;border-style:outset;border-collapse:collapse}table th{border-width:2px;padding:5px;border-style:inset}table td{border-width:1px;border-style:inset;line-height:18px;padding:5px 5px}table, table th, table td{border-left-style:none;border-right-style:none}table thead, table tr.even{background-color:#f7f7f7}p{margin:0.5em 0}sup, sub{position:relative;vertical-align:baseline;top:-0.4em}sub{top:0.4em}blockquote{background-color:#fffff6;padding:0.25em 0.75em}hr{border-style:solid;border:none;border-top:1px solid #777;margin:28px 0}dl{margin-left:0}dl dd{margin-bottom:13px;margin-left:13px}dl dt{font-weight:bold}ul{margin-top:0}ul li{list-style:circle outside}ul ul{margin-bottom:0}pre, code{background-color:#f7f7f7;border-radius:3px;color:#333;white-space:pre-wrap}pre{border-radius:3px;margin:5px 0px 10px 0px;padding:10px}pre:not([class]){background-color:#f7f7f7}code{font-size:85%; font-family:Consolas, Monaco, 'Lucida Console','Courier New', 'Courier', monospace}p > code, li > code{padding:2px 0px}div.figure{text-align:center}img{background-color:#FFF;padding:2px;border:1px solid #DDD;border-radius:5px;border:1px solid #CCC;margin:0 5px}h1{margin-top:0;padding-top:10px;padding-bottom:4px;border-bottom:3px solid #f7f7f7;font-size:175%;line-height:30px;letter-spacing:.5px}h2{border-bottom:2px solid #f7f7f7;padding-top:10px;padding-bottom:2px;font-size:145%}h3{border-bottom:1px solid #f7f7f7;padding-top:10px;font-size:120%}h4{margin-left:8px;font-size:110%}.author{font-size:91%;margin-left:0;margin-bottom:0;font-style:normal}h5, h6{border-bottom:1px solid #ccc;font-size:105%}a{color:#0033dd;text-decoration:none}a:hover{color:#6666ff}a:visited{color:#800080}a:visited:hover{color:#BB00BB}a[href^="http:"]{color:#696969;border-bottom:1px dotted #000}a[href^="https:"]{border-bottom:1px dotted #000;color:#696969}code > span.kw{color:#555;font-weight:bold} code > span.dt{color:#902000} code > span.dv{color:#40a070} code > span.bn{color:#d14} code > span.fl{color:#d14} code > span.ch{color:#d14} code > span.st{color:#d14} code > span.co{color:#888888;font-style:italic} code > span.ot{color:#007020} code > span.al{color:#ff0000;font-weight:bold} code > span.fu{color:#900;font-weight:bold}  code > span.er{color:#a61717;background-color:#e3d2d2} .top{display:inline;position:fixed;bottom:0;right:0;padding:0;font-size:108px;width:30px}.top img{border:none}a.toplink:link{background-image:url(data:image/png;base64,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);background-repeat:no-repeat;text-decoration:none;background-color:transparent;opacity:.6;filter:alpha(opacity=60);background-position:bottom 7px right;background-size:contain}a.toplink:hover,a.toplink:active{text-decoration:none;background-color:transparent;opacity:.4;filter:alpha(opacity=40);background-position:bottom 7px right;background-size:contain}code span.co{font-style:normal}#nav{position:absolute;top:0;float:left;background-color:#084262;border:none}#nav ul{width:100%;list-style-type:none;text-align:center;color:#fff;font-size:.75em;letter-spacing:2px;font-weight:700;margin:0;padding:0}#nav ul li{display:inline}#nav ul li a,#nav ul li span{color:#fff;background-color:#084262;text-decoration:none;float:left;border-right:1px solid #7394B4;cursor:pointer;padding:.5em 11.5px}#nav ul li a:hover,#nav ul li span{color:#fff;background-color:#257B9D}@media print{#nav,#TOC,#TOC .toctitle,#TOC ul,#TOC ul ul,#TOC li{display:none}}</style>




</head>

<body>




<h1 class="title toc-ignore">replicateBE</h1>
<h3 class="subtitle">Comparative BA-calculation for Average
Bioequivalence with Expanding Limits (ABEL)</h3>


<div id="TOC">
<ul>
<li><a href="#intro" id="toc-intro">Introduction</a></li>
<li><a href="#methods" id="toc-methods">Functions</a>
<ul>
<li><a href="#method.a" id="toc-method.a"><code id="methodA">method.A()</code></a></li>
<li><a href="#method.b" id="toc-method.b"><code id="methodB">method.B()</code></a></li>
<li><a href="#abe" id="toc-abe"><code id="ABE">ABE()</code></a></li>
</ul></li>
<li><a href="#hypotheses" id="toc-hypotheses">Hypotheses</a></li>
<li><a href="#designs" id="toc-designs">Tested designs</a>
<ul>
<li><a href="#per4_full" id="toc-per4_full">Four period (full)
replicates</a></li>
<li><a href="#per3_full" id="toc-per3_full">Three period (full)
replicates</a></li>
<li><a href="#per2_full" id="toc-per2_full">Two period (full)
replicate</a></li>
<li><a href="#per3_part" id="toc-per3_part">Three period (partial)
replicates</a></li>
</ul></li>
<li><a href="#data_struct" id="toc-data_struct">Data structure</a>
<ul>
<li><a href="#fmt" id="toc-fmt">Format</a></li>
<li><a href="#incomplete" id="toc-incomplete">Incomplete data</a></li>
</ul></li>
<li><a href="#notes" id="toc-notes">Notes on the methods</a>
<ul>
<li><a href="#cv" id="toc-cv">Estimation of intra-subject
variability</a></li>
<li><a href="#model_struc" id="toc-model_struc">Model structure</a></li>
<li><a href="#BElim" id="toc-BElim">BE limits, PE restriction, rounding
issues</a></li>
<li><a href="#df_comp" id="toc-df_comp">Degrees of freedom, comparison
of methods</a></li>
<li><a href="#ola" id="toc-ola">Outlier analysis</a></li>
</ul></li>
<li><a href="#app_out" id="toc-app_out">Applicability, caveats,
outlook</a></li>
<li><a href="#cross" id="toc-cross">Cross-validation</a></li>
<li><a href="#contr" id="toc-contr">Contributors</a></li>
<li><a href="#license" id="toc-license">License</a></li>
<li><a href="#disclaimer" id="toc-disclaimer">Disclaimer</a></li>
</ul>
</div>

<div class="top">
<a class="toplink" href="#" title="▲ top"> </a>
</div>
<div id="intro" class="section level1">
<h1>Introduction</h1>
<p>The package provides datasets (internal <code>.rda</code> and in
<abbr title="Character Separated Variables">CSV</abbr>-format in
<code>/extdata/</code>) which support users in a <a href="https://en.wikipedia.org/wiki/Black-box_testing">black-box</a>
performance qualification (PQ) of their software installations.<a href="#fn1" class="footnote-ref" id="fnref1"><sup>1</sup></a> Users can
analyze data imported from
<abbr title="Character Separated Variables">CSV</abbr>- and
Excel-files.</p>
<p>The methods<a href="#fn2" class="footnote-ref" id="fnref2"><sup>2</sup></a> given by the European Medicines Agency
(EMA) for reference-scaling according to the Guideline on the
Inves­tigation of Bioequivalence<a href="#fn3" class="footnote-ref" id="fnref3"><sup>3</sup></a> are implemented. Health Canada’s approach<a href="#fn4" class="footnote-ref" id="fnref4"><sup>4</sup></a> –
requiring a mixed-effects model – is approximated by intra-subject
contrasts. Direct widening of the limits for <em>C</em><sub>max</sub>
(as a special case of
<abbr title="Average Bioequivalence with Expanding Limits">ABEL</abbr>)
recommended by the
<abbr title="Gulf Cooperation Council: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, the United Arab Emirates.">GCC</abbr><a href="#fn5" class="footnote-ref" id="fnref5"><sup>5</sup></a> is
supported as well.</p>
<p>Potential influence of outliers on the variability of the reference
can be assessed by box plots of studentized and standardized residuals
as suggested at a joint
<abbr title="European Generic Medicines Association">EGA</abbr>/<abbr title="European Medicines Agency">EMA</abbr>
symposium.<a href="#fn6" class="footnote-ref" id="fnref6"><sup>6</sup></a></p>
</div>
<div id="methods" class="section level1">
<h1>Functions</h1>
<div id="method.a" class="section level2">
<h2><code id="methodA">method.A()</code></h2>
<p>A linear model of log-transformed
<abbr title="pharmacokinetic">PK</abbr> responses and effects<br />
    <em>sequence</em>, <em>subject</em>(<em>sequence</em>),
<em>period</em>, <em>treatment</em><br />
where all effects are fixed (<em>i.e.</em>, evaluated by an
<abbr title="Analysis of Variance">ANOVA</abbr>). Estimated via function
<code>lm()</code> of package <code>stats</code>.</p>
<div class="sourceCode" id="cb1"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb1-1"><a href="#cb1-1" aria-hidden="true" tabindex="-1"></a>modA <span class="ot">&lt;-</span> <span class="fu">lm</span>(<span class="fu">log</span>(PK) <span class="sc">~</span> sequence <span class="sc">+</span> subject<span class="sc">%in%</span>sequence <span class="sc">+</span> period <span class="sc">+</span> treatment,</span>
<span id="cb1-2"><a href="#cb1-2" aria-hidden="true" tabindex="-1"></a>                     <span class="at">data =</span> data)</span></code></pre></div>
</div>
<div id="method.b" class="section level2">
<h2><code id="methodB">method.B()</code></h2>
<p>A linear model of log-transformed
<abbr title="pharmacokinetic">PK</abbr> responses and effects<br />
    <em>sequence</em>, <em>subject</em>(<em>sequence</em>),
<em>period</em>, <em>treatment</em><br />
where <em>subject</em>(<em>sequence</em>) is a random effect and all
others are fixed.<br />
</p>
<p>Three options are provided</p>
<ol class="example" style="list-style-type: decimal">
<li>Estimated via function <code>lmer()</code> of package
<code>lmerTest</code>.</li>
</ol>
<div class="sourceCode" id="cb2"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb2-1"><a href="#cb2-1" aria-hidden="true" tabindex="-1"></a>modB <span class="ot">&lt;-</span> <span class="fu">lmer</span>(<span class="fu">log</span>(PK) <span class="sc">~</span> sequence <span class="sc">+</span> period <span class="sc">+</span> treatment <span class="sc">+</span> (<span class="dv">1</span><span class="sc">|</span>subject),</span>
<span id="cb2-2"><a href="#cb2-2" aria-hidden="true" tabindex="-1"></a>                       <span class="at">data =</span> data)</span></code></pre></div>
<ul>
<li>Employs Satterthwaite’s approximation<a href="#fn7" class="footnote-ref" id="fnref7"><sup>7</sup></a> of the degrees of
freedom <code>method.B(..., option = 1)</code>, which is equivalent to
SAS’ <code>DDFM=SATTERTHWAITE</code>, Phoenix WinNonlin’s
<code>Degrees of Freedom Satterthwaite</code>, and Stata’s
<code>dfm=Satterthwaite</code>.</li>
<li>Note that this is the only available approximation in SPSS.</li>
</ul>
<ol start="2" class="example" style="list-style-type: decimal">
<li>Estimated via function <code>lme()</code> of package
<code>nlme</code>.</li>
</ol>
<div class="sourceCode" id="cb3"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb3-1"><a href="#cb3-1" aria-hidden="true" tabindex="-1"></a>modB <span class="ot">&lt;-</span> <span class="fu">lme</span>(<span class="fu">log</span>(PK) <span class="sc">~</span> sequence <span class="sc">+</span>  period <span class="sc">+</span> treatment, <span class="at">random =</span> <span class="sc">~</span><span class="dv">1</span><span class="sc">|</span>subject,</span>
<span id="cb3-2"><a href="#cb3-2" aria-hidden="true" tabindex="-1"></a>                      <span class="at">data =</span> data)</span></code></pre></div>
<ul>
<li>Employs degrees of freedom equivalent to SAS’
<code>DDFM=CONTAIN</code> (implicitly preferred by the
<abbr title="European Medicines Agency">EMA</abbr>), Phoenix WinNonlin’s
<code>Degrees of Freedom Residual</code>, STATISTICA’s
<code>GLM containment</code>, and Stata’s <code>dfm=anova</code>.</li>
<li>To comply with the
<abbr title="European Medicines Agency">EMA</abbr>’s
<abbr title="Questions &amp; Answers">Q&amp;A</abbr> document,
<code>method.B(..., option = 2)</code> is the default (<em>i.e.</em>, if
the argument <code>option</code> is missing).</li>
</ul>
<ol start="3" class="example" style="list-style-type: decimal">
<li>Estimated via function <code>lmer()</code> of package
<code>lmerTest</code>.</li>
</ol>
<div class="sourceCode" id="cb4"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb4-1"><a href="#cb4-1" aria-hidden="true" tabindex="-1"></a>modB <span class="ot">&lt;-</span> <span class="fu">lmer</span>(<span class="fu">log</span>(PK) <span class="sc">~</span> sequence <span class="sc">+</span> period <span class="sc">+</span> treatment <span class="sc">+</span> (<span class="dv">1</span><span class="sc">|</span>subject),</span>
<span id="cb4-2"><a href="#cb4-2" aria-hidden="true" tabindex="-1"></a>                       <span class="at">data =</span> data)</span></code></pre></div>
<ul>
<li>Employs the Kenward-Roger approximation<a href="#fn8" class="footnote-ref" id="fnref8"><sup>8</sup></a> of the degrees of
freedom <code>method.B(..., option = 3)</code>, which is equivalent to
Stata’s <code>dfm=Kenward Roger (EIM)</code> and SAS’
<code>DDFM=KENWARDROGER(FIRSTORDER)</code>, <em>i.e.</em>, based on the
<em>expected</em> information matrix.</li>
<li>Note that SAS with <code>DDFM=KENWARDROGER</code> and JMP calculate
Satterthwaite’s [<em>sic</em>] degrees of freedom and apply the
Kackar-Harville correction<a href="#fn9" class="footnote-ref" id="fnref9"><sup>9</sup></a> <em>i.e.</em>, based on the
<em>observed</em> information matrix.</li>
</ul>
</div>
<div id="abe" class="section level2">
<h2><code id="ABE">ABE()</code></h2>
<p>Average Bioequivalence, where the model is identical to <a href="#methodA">Method A</a>. By default the conventional acceptance
range of 80.00 – 125.00% is used. Tighter limits (90.00 – 111.11%) for
narrow therapeutic index drugs
(<abbr title="European Medicines Agency">EMA</abbr> and others) or wider
limits (75.00 – 133.33% for <em>C</em><sub>max</sub> according to the
guideline of South Africa<a href="#fn10" class="footnote-ref" id="fnref10"><sup>10</sup></a>) can be specified by the arguments
<code>theta1</code> (lower limit) and/or <code>theta2</code> (upper
limit).</p>
</div>
</div>
<div id="hypotheses" class="section level1">
<h1>Hypotheses</h1>
<p>The hypotheses in the confidence interval inclusion approach are
<span class="math display">\[\small{H_{0}:
\frac{\mu_\textrm{T}}{\mu_\textrm{R}}\ni
\left\{L,U\right\}\:vs\:H_{1}:L&lt;\frac{\mu_\textrm{T}}{\mu_\textrm{R}}&lt;U}\]</span>
where the null hypothesis is <strong>in</strong>equivalence. In Average
Bioequivalence (ABE) the limits <span class="math inline">\(\small{\left\{L,U\right\}}\)</span> are
<em>fixed</em>, whereas in
<abbr title="Average Bioequivalence with Expanding Limits">ABEL</abbr>
they can be <a href="#BElim"><em>expanded</em></a> based on the
within-subject variability of the reference treatment.</p>
</div>
<div id="designs" class="section level1">
<h1>Tested designs</h1>
<p>Details about the reference datasets and their designs:</p>
<div class="sourceCode" id="cb5"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb5-1"><a href="#cb5-1" aria-hidden="true" tabindex="-1"></a><span class="fu">help</span>(<span class="st">&quot;data&quot;</span>, <span class="at">package =</span> <span class="st">&quot;replicateBE&quot;</span>)</span>
<span id="cb5-2"><a href="#cb5-2" aria-hidden="true" tabindex="-1"></a>?replicateBE<span class="sc">::</span>data</span></code></pre></div>
<div id="per4_full" class="section level2">
<h2>Four period (full) replicates</h2>
<p>Both the test and the reference treatments are administered at least
once.</p>
<div id="per4_full_2" class="section level3">
<h3>Two sequences</h3>
<p><code>TRTR | RTRT</code><br />
<code>TRRT | RTTR</code><br />
<code>TTRR | RRTT</code></p>
</div>
<div id="per4_full_4" class="section level3">
<h3>Four sequences</h3>
<p><code>TRTR | RTRT | TRRT | RTTR</code><br />
<code>TRRT | RTTR | TTRR | RRTT</code></p>
</div>
</div>
<div id="per3_full" class="section level2">
<h2>Three period (full) replicates</h2>
<p>The test treatment is administered at least once to ½ of the subjects
and the reference treatment at least once to the respective other ½ of
the subjects.</p>
<p><code>TRT | RTR</code><br />
<code>TRR | RTT</code></p>
</div>
<div id="per2_full" class="section level2">
<h2>Two period (full) replicate</h2>
<p>The test and reference treatments are administered once to ½ of the
subjects (for the estimation of the
<abbr title="Confidence Interval">CI</abbr>), <em>i.e.</em>, the first
group of subjects follows a conventional
<abbr title="2-treatment 2-sequence 2-period crossover">2×2×2</abbr>
trial. In the second group the test and reference treatments are
administered at least once to ¼ of the subjects, respectively (for the
estimation of <em>CV</em><sub>wT</sub> and
<em>CV</em><sub>wR</sub>).</p>
<p><code>TR | RT | TT | RR</code></p>
<p>Although supported, Balaam’s design<a href="#fn11" class="footnote-ref" id="fnref11"><sup>11</sup></a> is <em>not
recommended</em> due to its poor power characteristics.</p>
</div>
<div id="per3_part" class="section level2">
<h2>Three period (partial) replicates</h2>
<p>The test treatment is administered once and the reference treatment
at least once.</p>
<p><code>TRR | RTR | RRT</code><br />
<code>TRR | RTR</code></p>
<p>The latter is the so-called extra-reference design<a href="#fn12" class="footnote-ref" id="fnref12"><sup>12</sup></a> which is <em>not
recommended</em> since it is biased in the presence of period
effects.</p>
</div>
</div>
<div id="data_struct" class="section level1">
<h1>Data structure</h1>
<p>Columns must have the headers <code>subject</code>,
<code>period</code>, <code>sequence</code>, <code>treatment</code>,
<code>PK</code>, and/or <code>logPK</code>.<a href="#fn13" class="footnote-ref" id="fnref13"><sup>13</sup></a> Any order of columns
is acceptable. Uppercase and mixed case headers will be internally
converted to lowercase headers.</p>
<div id="fmt" class="section level2">
<h2>Format</h2>
<table>
<colgroup>
<col width="16%" />
<col width="83%" />
</colgroup>
<thead>
<tr class="header">
<th>Variable</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><code>subject</code></td>
<td>Integers or any combination of alphanumeric characters
(<code>A-Z</code>, <code>a-z</code>, <code>-</code>, <code>_</code>,
<code>#</code>, <code>0-9</code>)</td>
</tr>
<tr class="even">
<td><code>period</code></td>
<td>Integers</td>
</tr>
<tr class="odd">
<td><code>sequence</code></td>
<td>Numbers or literal sequences not listed in the <a href="#designs">tested designs</a> are not accepted (<em>e.g.</em>,
<strong><code>ABAB</code></strong>).</td>
</tr>
<tr class="even">
<td><code>treatment</code></td>
<td>The Test treatment must be coded <strong><code>T</code></strong> and
the Reference <strong><code>R</code></strong> (both uppercase).</td>
</tr>
<tr class="odd">
<td><code>PK</code></td>
<td>Real positive numbers of <abbr title="pharmacokinetic">PK</abbr>
responses.</td>
</tr>
<tr class="even">
<td><code>logPK</code></td>
<td>Real numbers of already log<sub>e</sub>-transformed PK responses
(optional and rarely needed).</td>
</tr>
</tbody>
</table>
<p>Relevant data are used for the estimation of <em>CV</em><sub>wR</sub>
(and <em>CV</em><sub>wT</sub> in full replicate designs) and BE,
<em>i.e.</em>, the data­sets might be different (see the <a href="#setexpl">example below</a>). It is good practice to state that in
the Statistical Analysis Plan.</p>
</div>
<div id="incomplete" class="section level2">
<h2>Incomplete data</h2>
<div id="setCW" class="section level3">
<h3>Estimation of <em>CV</em><sub>w</sub></h3>
<p>If a subject drops out from the study in a higher period, data of
repeated administrations will still be used for the estimation of
<em>CV</em><sub>w</sub>, although data of the other treatment might be
missing. Examples for the estimation of <em>CV</em><sub>wR</sub>
(missing values are denoted by <code>·</code>):<br />
</p>
<p><code>RTRT</code> | <code>RTR·</code><br />
<code>TRRT</code> | <code>TRR·</code><br />
<code>RRTT</code> | <code>RRT·</code> or <code>RR··</code><br />
<code>RRT</code> | <code>RR··</code><br />
</p>
</div>
<div id="setBE" class="section level3">
<h3>Assessment of BE</h3>
<p>If a subject drops out from the study in a higher period, data with
at least one administration of the Test and Reference will be used in
the assessment of BE. Examples (missing values are denoted by
<code>·</code>):<br />
</p>
<p><code>TRTR</code> | <code>TRT·</code> or | <code>TR··</code><br />
<code>RTRT</code> | <code>RTR·</code> or | <code>RT··</code><br />
<code>TRRT</code> | <code>TRR·</code> or | <code>TR··</code><br />
<code>RTTR</code> | <code>RTT·</code> or | <code>RT··</code><br />
<code>TTRR</code> | <code>TTR.</code><br />
<code>TRT</code> | <code>TR·</code><br />
<code>RTR</code> | <code>RT·</code><br />
<code>TRR</code> | <code>TR·</code><br />
<code>RTR</code> | <code>RT·</code><br />
<code>RTT</code> | <code>RT·</code><br />
</p>
</div>
<div id="setexpl" class="section level3">
<h3>Example of different datasets</h3>
<p>16 subjects enrolled in the study. In sequence <code>RTRT</code> one
dropout in the 2<sup>nd</sup> period and one in the 4<sup>th</sup>
period. In sequence <code>TRTR</code> one dropout in the 3<sup>rd</sup>
period and one in the 4<sup>th</sup>.<br />
</p>
<p><code>1  RTR.    5  RTRT    9  TRTR   13  RTRT</code><br />
<code>2  RTRT    6  TR··   10  TRTR   14  TRT·</code><br />
<code>3  RTRT    7  RTRT   11  RTRT   15  TRTR</code><br />
<code>4  TRTR    8  R···   12  TRTR   16  TRTR</code></p>
<p>We obtain these datasets:</p>
<table style="width:100%;">
<colgroup>
<col width="13%" />
<col width="21%" />
<col width="43%" />
<col width="21%" />
</colgroup>
<thead>
<tr class="header">
<th align="center">Dataset</th>
<th>Purpose</th>
<th>included</th>
<th align="center">excluded</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="center">#1</td>
<td>Estimation of <em>CV</em><sub>wR</sub></td>
<td>13 who received 2 treatments <code>R</code></td>
<td align="center">6, 8, 14</td>
</tr>
<tr class="even">
<td align="center">#2</td>
<td>Assessment of BE</td>
<td>15 who received ≥1 treatment <code>T</code> <em>and</em> ≥1
treatment <code>R</code></td>
<td align="center">8</td>
</tr>
<tr class="odd">
<td align="center">#3</td>
<td>Estimation of <em>CV</em><sub>wT</sub></td>
<td>13 who received 2 treatments <code>T</code></td>
<td align="center">1, 6, 8</td>
</tr>
</tbody>
</table>
<p>Datasets #1 and #2 are required for
<abbr title="Average Bioequivalence with Expanding Limits">ABEL</abbr>,
whereas for <abbr title="Average Bioequivalence">ABE</abbr> only dataset
#2 is required.<br />
Formerly all three were required for the
<abbr title="World Health Organization">WHO</abbr>’s reference-scaling
of <em>AUC</em> (see <a href="#app_out">below</a>).</p>
</div>
</div>
</div>
<div id="notes" class="section level1">
<h1>Notes on the methods</h1>
<div id="cv" class="section level2">
<h2>Estimation of intra-subject variability</h2>
<p>The <abbr title="European Medicines Agency">EMA</abbr> proposed a
linear model of log-transformed <abbr title="pharmacokinetic">PK</abbr>
responses of the reference treatment<br />
    <em>sequence</em>, <em>subject</em>(<em>sequence</em>),
<em>period</em><br />
where all effects are fixed. Estimated via function <code>lm()</code> of
package <code>stats</code>:</p>
<div class="sourceCode" id="cb6"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb6-1"><a href="#cb6-1" aria-hidden="true" tabindex="-1"></a>modCV <span class="ot">&lt;-</span> <span class="fu">lm</span>(<span class="fu">log</span>(PK) <span class="sc">~</span> sequence <span class="sc">+</span> subject<span class="sc">%in%</span>sequence <span class="sc">+</span> period,</span>
<span id="cb6-2"><a href="#cb6-2" aria-hidden="true" tabindex="-1"></a>                      <span class="at">data =</span> data[data<span class="sc">$</span><span class="at">treatment =</span> <span class="st">&quot;R&quot;</span>, ])</span></code></pre></div>
<p>In full replicate designs the same model is run with
<code>data = data[data$treatment = &quot;T&quot;, ]</code> for informational
purposes.</p>
<p>Special conditions for the sample size in three period full replicate
designs:</p>
<blockquote>
<p><em>The question raised asks if it is possible to use a design where
subjects are randomised to receive treatments in the order of TRT or
RTR.</em></p>
<p><em>The CHMP bioequivalence guideline requires that at least 12
patients are needed to provide data for a bioequivalence study to be
considered valid, and to estimate all the key parameters. Therefore, if
a 3-period replicate design, where treatments are given in the order TRT
or RTR, is to be used to justify widening of a confidence interval for
C<sub>max</sub> then it is considered that at least 12 patients would
need to provide data from the RTR arm. This implies a study with at
least 24 patients in total would be required if equal number of subjects
are allocated to the 2 treatment sequences.</em></p>
<p>— Q&amp;A document<a href="#fn14" class="footnote-ref" id="fnref14"><sup>14</sup></a></p>
</blockquote>
<p>If less than twelve subjects are eligible in sequence
<code>RTR</code> of a <code>TRT | RTR</code> design (and in analogy in
sequence <code>TRR</code> of a <code>TRR | RTT</code> design), the user
is notified about the ‘uncertain’ estimate of <em>CV</em><sub>wR</sub>.
However, in a sufficiently powered study such a case is <a href="https://forum.bebac.at/forum_entry.php?id=15139" title="BEBA Forum, 23 July 2015">extremely unlikely</a>.<br />
Let us explore the 95% confidence interval of the <em>CV</em>:</p>
<div class="sourceCode" id="cb7"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb7-1"><a href="#cb7-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Estimate sample sizes of full replicate designs (theta0 0.90,</span></span>
<span id="cb7-2"><a href="#cb7-2" aria-hidden="true" tabindex="-1"></a><span class="co"># target power 0.80) and CI of the CV with package PowerTOST</span></span>
<span id="cb7-3"><a href="#cb7-3" aria-hidden="true" tabindex="-1"></a>CV     <span class="ot">&lt;-</span> <span class="fl">0.30</span></span>
<span id="cb7-4"><a href="#cb7-4" aria-hidden="true" tabindex="-1"></a>design <span class="ot">&lt;-</span> <span class="fu">c</span>(<span class="st">&quot;2x2x4&quot;</span>, <span class="st">&quot;2x2x3&quot;</span>) <span class="co"># 4- and 3-period full replicate designs</span></span>
<span id="cb7-5"><a href="#cb7-5" aria-hidden="true" tabindex="-1"></a>res    <span class="ot">&lt;-</span> <span class="fu">data.frame</span>(<span class="at">design =</span> <span class="fu">rep</span>(design, <span class="dv">2</span>), <span class="at">n =</span> <span class="fu">c</span>(<span class="fu">rep</span>(<span class="cn">NA</span>, <span class="dv">2</span>), <span class="fu">rep</span>(<span class="dv">12</span>, <span class="dv">2</span>)),</span>
<span id="cb7-6"><a href="#cb7-6" aria-hidden="true" tabindex="-1"></a>                     <span class="at">df =</span> <span class="cn">NA</span>, <span class="at">CV =</span> CV, <span class="at">lower =</span> <span class="cn">NA</span>, <span class="at">upper =</span> <span class="cn">NA</span>)</span>
<span id="cb7-7"><a href="#cb7-7" aria-hidden="true" tabindex="-1"></a><span class="co"># 95% confidence interval of the CV</span></span>
<span id="cb7-8"><a href="#cb7-8" aria-hidden="true" tabindex="-1"></a><span class="cf">for</span> (i <span class="cf">in</span> <span class="dv">1</span><span class="sc">:</span><span class="fu">nrow</span>(res)) {</span>
<span id="cb7-9"><a href="#cb7-9" aria-hidden="true" tabindex="-1"></a>  <span class="cf">if</span> (<span class="fu">is.na</span>(res<span class="sc">$</span>n[i])) {</span>
<span id="cb7-10"><a href="#cb7-10" aria-hidden="true" tabindex="-1"></a>    res<span class="sc">$</span>n[i] <span class="ot">&lt;-</span> PowerTOST<span class="sc">::</span><span class="fu">sampleN.scABEL</span>(<span class="at">CV =</span> CV,</span>
<span id="cb7-11"><a href="#cb7-11" aria-hidden="true" tabindex="-1"></a>                                          <span class="at">design =</span> res<span class="sc">$</span>design[i],</span>
<span id="cb7-12"><a href="#cb7-12" aria-hidden="true" tabindex="-1"></a>                                          <span class="at">details =</span> <span class="cn">FALSE</span>,</span>
<span id="cb7-13"><a href="#cb7-13" aria-hidden="true" tabindex="-1"></a>                                          <span class="at">print =</span> <span class="cn">FALSE</span>)[[<span class="st">&quot;Sample size&quot;</span>]]</span>
<span id="cb7-14"><a href="#cb7-14" aria-hidden="true" tabindex="-1"></a>  }</span>
<span id="cb7-15"><a href="#cb7-15" aria-hidden="true" tabindex="-1"></a>  <span class="cf">if</span> (i <span class="sc">&gt;</span> <span class="dv">2</span> ) {</span>
<span id="cb7-16"><a href="#cb7-16" aria-hidden="true" tabindex="-1"></a>    n<span class="fl">.1</span> <span class="ot">&lt;-</span> res<span class="sc">$</span>n[i<span class="dv">-2</span>] <span class="sc">/</span> <span class="dv">2</span> <span class="co"># no dropouts in one sequence</span></span>
<span id="cb7-17"><a href="#cb7-17" aria-hidden="true" tabindex="-1"></a>    n<span class="fl">.2</span> <span class="ot">&lt;-</span> <span class="dv">12</span>             <span class="co"># only 12 eligible subjects in the other</span></span>
<span id="cb7-18"><a href="#cb7-18" aria-hidden="true" tabindex="-1"></a>    res<span class="sc">$</span>n[i] <span class="ot">&lt;-</span> n<span class="fl">.1</span> <span class="sc">+</span> n<span class="fl">.2</span></span>
<span id="cb7-19"><a href="#cb7-19" aria-hidden="true" tabindex="-1"></a>  }</span>
<span id="cb7-20"><a href="#cb7-20" aria-hidden="true" tabindex="-1"></a>  <span class="cf">if</span> (res<span class="sc">$</span>design[i] <span class="sc">==</span> <span class="st">&quot;2x2x4&quot;</span>) {</span>
<span id="cb7-21"><a href="#cb7-21" aria-hidden="true" tabindex="-1"></a>    res<span class="sc">$</span>df[i] <span class="ot">&lt;-</span> <span class="dv">3</span> <span class="sc">*</span> res<span class="sc">$</span>n[i] <span class="sc">-</span> <span class="dv">4</span></span>
<span id="cb7-22"><a href="#cb7-22" aria-hidden="true" tabindex="-1"></a>  } <span class="cf">else</span> {</span>
<span id="cb7-23"><a href="#cb7-23" aria-hidden="true" tabindex="-1"></a>    res<span class="sc">$</span>df[i] <span class="ot">&lt;-</span> <span class="dv">2</span> <span class="sc">*</span> res<span class="sc">$</span>n[i] <span class="sc">-</span> <span class="dv">3</span></span>
<span id="cb7-24"><a href="#cb7-24" aria-hidden="true" tabindex="-1"></a>  }</span>
<span id="cb7-25"><a href="#cb7-25" aria-hidden="true" tabindex="-1"></a>  res[i, <span class="dv">5</span><span class="sc">:</span><span class="dv">6</span>] <span class="ot">&lt;-</span> <span class="fu">round</span>(PowerTOST<span class="sc">::</span><span class="fu">CVCL</span>(<span class="at">CV =</span> CV,</span>
<span id="cb7-26"><a href="#cb7-26" aria-hidden="true" tabindex="-1"></a>                                       <span class="at">df =</span> res<span class="sc">$</span>df[i],</span>
<span id="cb7-27"><a href="#cb7-27" aria-hidden="true" tabindex="-1"></a>                                       <span class="at">side =</span> <span class="st">&quot;2-sided&quot;</span>,</span>
<span id="cb7-28"><a href="#cb7-28" aria-hidden="true" tabindex="-1"></a>                                       <span class="at">alpha =</span> <span class="fl">0.05</span>), <span class="dv">3</span>)</span>
<span id="cb7-29"><a href="#cb7-29" aria-hidden="true" tabindex="-1"></a>}</span>
<span id="cb7-30"><a href="#cb7-30" aria-hidden="true" tabindex="-1"></a><span class="fu">print</span>(res, <span class="at">row.names =</span> <span class="cn">FALSE</span>)</span>
<span id="cb7-31"><a href="#cb7-31" aria-hidden="true" tabindex="-1"></a><span class="co">#  design  n df  CV lower upper</span></span>
<span id="cb7-32"><a href="#cb7-32" aria-hidden="true" tabindex="-1"></a><span class="co">#   2x2x4 34 98 0.3 0.262 0.351</span></span>
<span id="cb7-33"><a href="#cb7-33" aria-hidden="true" tabindex="-1"></a><span class="co">#   2x2x3 50 97 0.3 0.262 0.352</span></span>
<span id="cb7-34"><a href="#cb7-34" aria-hidden="true" tabindex="-1"></a><span class="co">#   2x2x4 29 83 0.3 0.259 0.357</span></span>
<span id="cb7-35"><a href="#cb7-35" aria-hidden="true" tabindex="-1"></a><span class="co">#   2x2x3 37 71 0.3 0.256 0.362</span></span>
<span id="cb7-36"><a href="#cb7-36" aria-hidden="true" tabindex="-1"></a><span class="co"># Rows 1-2: Sample sizes for target power</span></span>
<span id="cb7-37"><a href="#cb7-37" aria-hidden="true" tabindex="-1"></a><span class="co"># Rows 3-4: Only 12 eligible subjects in one sequence</span></span></code></pre></div>
<p>It is incomprehensible why a four period full replicate design is
considered by the <abbr title="European Medicines Agency">EMA</abbr> to
give a more ‘reliable’ estimate of the <em>CV</em> than a three period
full replicate design.</p>
</div>
<div id="model_struc" class="section level2">
<h2>Model structure</h2>
<p>The <abbr title="European Medicines Agency">EMA</abbr>’s models
assume equal [<em>sic</em>] intra-subject variances of Test and
Reference (like in
<abbr title="2-treatment 2-sequence 2-period crossover">2×2×2</abbr>
trials) – even if proven false in one of the full replicate designs
(were <em>both</em> <em>CV</em><sub>wT</sub> and
<em>CV</em><sub>wR</sub> can be estimated). Hence, among
biostatisticians they are called ‘crippled models’ because the
replicative nature of the study is ignored.</p>
<p>It should be noted that by default <code>ANOVA()</code> produces a
‘Type I’ table, <em>i.e.</em>, all tests are performed against the
residual error. Starting with version 1.1.0 ‘Type III’ is employed in
order to obtain the correct test for carryover, where <em>subject</em>
has to be tested against <em>subject</em>(<em>sequence</em>).<a href="#fn15" class="footnote-ref" id="fnref15"><sup>15</sup></a></p>
<div class="sourceCode" id="cb8"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb8-1"><a href="#cb8-1" aria-hidden="true" tabindex="-1"></a><span class="fu">library</span>(replicateBE) <span class="co"># attach the library to run example scripts</span></span>
<span id="cb8-2"><a href="#cb8-2" aria-hidden="true" tabindex="-1"></a><span class="fu">method.A</span>(<span class="at">data =</span> rds01, <span class="at">print =</span> <span class="cn">FALSE</span>, <span class="at">verbose=</span><span class="cn">TRUE</span>)</span>
<span id="cb8-3"><a href="#cb8-3" aria-hidden="true" tabindex="-1"></a><span class="co"># </span></span>
<span id="cb8-4"><a href="#cb8-4" aria-hidden="true" tabindex="-1"></a><span class="co"># Data set DS01: Method A by lm() </span></span>
<span id="cb8-5"><a href="#cb8-5" aria-hidden="true" tabindex="-1"></a><span class="co"># ─────────────────────────────────── </span></span>
<span id="cb8-6"><a href="#cb8-6" aria-hidden="true" tabindex="-1"></a><span class="co"># Type III Analysis of Variance Table</span></span>
<span id="cb8-7"><a href="#cb8-7" aria-hidden="true" tabindex="-1"></a><span class="co"># </span></span>
<span id="cb8-8"><a href="#cb8-8" aria-hidden="true" tabindex="-1"></a><span class="co"># Response: log(PK)</span></span>
<span id="cb8-9"><a href="#cb8-9" aria-hidden="true" tabindex="-1"></a><span class="co">#                   Df   Sum Sq  Mean Sq  F value     Pr(&gt;F)</span></span>
<span id="cb8-10"><a href="#cb8-10" aria-hidden="true" tabindex="-1"></a><span class="co"># sequence           1   0.0077 0.007652  0.00268  0.9588496</span></span>
<span id="cb8-11"><a href="#cb8-11" aria-hidden="true" tabindex="-1"></a><span class="co"># period             3   0.6984 0.232784  1.45494  0.2278285</span></span>
<span id="cb8-12"><a href="#cb8-12" aria-hidden="true" tabindex="-1"></a><span class="co"># treatment          1   1.7681 1.768098 11.05095  0.0010405</span></span>
<span id="cb8-13"><a href="#cb8-13" aria-hidden="true" tabindex="-1"></a><span class="co"># sequence:subject  75 214.1296 2.855061 17.84467 &lt; 2.22e-16</span></span>
<span id="cb8-14"><a href="#cb8-14" aria-hidden="true" tabindex="-1"></a><span class="co"># Residuals        217  34.7190 0.159995                    </span></span>
<span id="cb8-15"><a href="#cb8-15" aria-hidden="true" tabindex="-1"></a><span class="co"># </span></span>
<span id="cb8-16"><a href="#cb8-16" aria-hidden="true" tabindex="-1"></a><span class="co"># treatment T – R:</span></span>
<span id="cb8-17"><a href="#cb8-17" aria-hidden="true" tabindex="-1"></a><span class="co">#   Estimate Std. Error    t value   Pr(&gt;|t|) </span></span>
<span id="cb8-18"><a href="#cb8-18" aria-hidden="true" tabindex="-1"></a><span class="co"># 0.14547400 0.04650870 3.12788000 0.00200215 </span></span>
<span id="cb8-19"><a href="#cb8-19" aria-hidden="true" tabindex="-1"></a><span class="co"># 217 Degrees of Freedom</span></span></code></pre></div>
<p>In ‘Type I’ the <em>F</em> value of <em>sequence</em> would be <span class="math inline">\(\small{\frac{0.007652}{0.159995}=0.04783}\)</span>
with <span class="math inline">\(\small{p(F_{q=0.04783,\,df_1=1,\,df_2=217})\sim
0.827}\)</span>, whereas in ‘Type III’ it is <span class="math inline">\(\small{\frac{0.007652}{2.855061}=0.00268}\)</span>
with <span class="math inline">\(\small{p(F_{q=0.00268,\,df_1=1,\,df_2=75})\sim
0.959}\)</span>.</p>
<p>The nested structure <em>subject</em>(<em>sequence</em>) of the <a href="#methods">methods</a> leads to an over-specified model.<a href="#fn16" class="footnote-ref" id="fnref16"><sup>16</sup></a> The
simple model<br />
    <em>sequence</em>, <em>subject</em>, <em>period</em>,
<em>treatment</em><br />
gives identical estimates of the residual variance and the treatment
effect and hence, its confidence interval.</p>
<p>The same holds true for the <a href="#cv">EMA’s model</a> to estimate
<em>CV</em><sub>wR</sub>. The simple model<br />
    <em>subject</em>, <em>period</em><br />
gives an identical estimate of the residual variance.</p>
<p>Reference-scaling is acceptable for <em>C</em><sub>max</sub>
(immediate release products: <abbr title="Bioequivalence">BE</abbr>
Guideline) and <em>C</em><sub>max</sub>, <em>C</em><sub>max,ss</sub>,
<em>C</em><sub>τ,ss</sub>, <sub>partial</sub><em>AUC</em> (modified
release products<a href="#fn17" class="footnote-ref" id="fnref17"><sup>17</sup></a>). The intention to expand the limits has
to be stated in the protocol and – contrary to the
<abbr title="U.S. Food and Drug Administration">FDA</abbr>’s
<abbr title="Reference Scaled Average Bioequivalence">RSABE</abbr> – a
clinical justification provided.</p>
<blockquote>
<p><em>Those <abbr title="Highly Variable Drug Product">HVDP</abbr> for
which a wider difference in C<sub>max</sub> is considered clinically
irrelevant based on a sound clinical justification can be assessed with
a widened acceptance range. The request for widened interval must be
prospectively specified in the protocol.</em></p>
<p>— CHMP Bioequivalence Guideline</p>
</blockquote>
</div>
<div id="BElim" class="section level2">
<h2>BE limits, PE restriction, rounding issues</h2>
<p>The limits can be expanded based on <em>CV</em><sub>wR</sub>.</p>
<ul>
<li><span class="math inline">\(\small{CV_\textrm{wR}\leq
30\%}\)</span><br />
Lower cap, <em>i.e.</em>, no scaling, conventional limits:<br />
<span class="math inline">\(\small{\left\{{L,U}\right\} = 80.00 -
125.00\%}\)</span></li>
<li><span class="math inline">\(\small{30\%&lt;CV_\textrm{wR}\leq
50\%}\)</span> (EMA), <span class="math inline">\(\small{30\%&lt;CV_\textrm{wR}\leq
\sim57.4\%}\)</span> (Health Canada)<br />
Expanded limits based on <span class="math inline">\(s_\textrm{wR}\)</span>:<br />
<span class="math inline">\(\small{\left\{L,\,U\right\} = 100\cdot
\exp(\mp 0.760\cdot{s_\textrm{wR}})}\)</span></li>
<li><span class="math inline">\(\small{CV_\textrm{wR}&gt;50\%}\)</span>
(EMA), <span class="math inline">\(\small{CV_\textrm{wR}&gt;\sim57.4\%}\)</span><br />
Upper cap, <em>i.e.</em>, applying <span class="math inline">\(\small{s^*_\textrm{wR}=\sqrt{\log_{e}(CV_\textrm{cap}^{2}+1)}}\)</span>
in the expansion formula or<br />
<span class="math inline">\(\small{\left\{L,U\right\} = 69.84 -
143.19\%}\)</span> (EMA)<br />
<span class="math inline">\(\small{\left\{L,U\right\} = 66.7 -
150.0\%}\)</span> (Health Canada).</li>
</ul>
<p>The special case recommended by the Gulf Cooperation Council
(Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, the United Arab Emirates)
is:</p>
<ul>
<li><span class="math inline">\(\small{CV_\textrm{wR}\leq
30\%}\)</span><br />
Lower cap, <em>i.e.</em>, no scaling, conventional limits:<br />
<span class="math inline">\(\small{\left\{{L,U}\right\} = 80.00 -
125.00\%}\)</span><br />
</li>
<li><span class="math inline">\(\small{CV_\textrm{wR}&gt;30\%}\)</span><br />
Widened limits:<br />
<span class="math inline">\(\small{\left\{{L,U}\right\} = 75.00 -
133.33\%}\)</span></li>
</ul>
<p>In reference-scaling a so-called <em>mixed</em> (a.k.a.
<em>aggregate</em>) criterion is applied. In order to pass
<abbr title="Average Bioequivalence with Expanding Limits">ABEL</abbr>,</p>
<ul>
<li>the 90% confidence interval has to lie entirely within the
acceptance range <span class="math inline">\(\small{\left\{L,U\right\}}\)</span>
<em>and</em></li>
<li>the point estimate (PE) has to lie within 80.00 – 125.00%.</li>
</ul>
<p>To avoid discontinuities due to double rounding, expanded limits are
calculated in full numeric precision and only the confidence interval is
rounded according to the guidelines.</p>
<div class="sourceCode" id="cb9"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb9-1"><a href="#cb9-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Calculate limits with package PowerTOST</span></span>
<span id="cb9-2"><a href="#cb9-2" aria-hidden="true" tabindex="-1"></a>CV <span class="ot">&lt;-</span> <span class="fu">c</span>(<span class="dv">30</span>, <span class="dv">50</span>, <span class="fl">57.382</span>)</span>
<span id="cb9-3"><a href="#cb9-3" aria-hidden="true" tabindex="-1"></a>df <span class="ot">&lt;-</span> <span class="fu">data.frame</span>(<span class="at">CV =</span> CV,</span>
<span id="cb9-4"><a href="#cb9-4" aria-hidden="true" tabindex="-1"></a>                 <span class="at">reg1 =</span> <span class="st">&quot;EMA&quot;</span>, <span class="at">L1 =</span> <span class="cn">NA</span>, <span class="at">U1 =</span> <span class="cn">NA</span>, <span class="at">cap1 =</span> <span class="st">&quot;&quot;</span>,</span>
<span id="cb9-5"><a href="#cb9-5" aria-hidden="true" tabindex="-1"></a>                 <span class="at">reg2 =</span> <span class="st">&quot;HC&quot;</span>,  <span class="at">L2 =</span> <span class="cn">NA</span>, <span class="at">U2 =</span> <span class="cn">NA</span>, <span class="at">cap2 =</span> <span class="st">&quot;&quot;</span>,</span>
<span id="cb9-6"><a href="#cb9-6" aria-hidden="true" tabindex="-1"></a>                 <span class="at">reg3 =</span> <span class="st">&quot;GCC&quot;</span>, <span class="at">L3 =</span> <span class="cn">NA</span>, <span class="at">U3 =</span> <span class="cn">NA</span>, <span class="at">cap3 =</span> <span class="st">&quot;&quot;</span>,</span>
<span id="cb9-7"><a href="#cb9-7" aria-hidden="true" tabindex="-1"></a>                 <span class="at">stringsAsFactors =</span> <span class="cn">FALSE</span>)</span>
<span id="cb9-8"><a href="#cb9-8" aria-hidden="true" tabindex="-1"></a><span class="cf">for</span> (i <span class="cf">in</span> <span class="fu">seq_along</span>(CV)) {</span>
<span id="cb9-9"><a href="#cb9-9" aria-hidden="true" tabindex="-1"></a>  df[i, <span class="dv">3</span><span class="sc">:</span><span class="dv">4</span>]   <span class="ot">&lt;-</span> <span class="fu">sprintf</span>(<span class="st">&quot;%.3f&quot;</span>,</span>
<span id="cb9-10"><a href="#cb9-10" aria-hidden="true" tabindex="-1"></a>                          PowerTOST<span class="sc">::</span><span class="fu">scABEL</span>(CV[i]<span class="sc">/</span><span class="dv">100</span>,</span>
<span id="cb9-11"><a href="#cb9-11" aria-hidden="true" tabindex="-1"></a>                                            <span class="at">regulator =</span> df<span class="sc">$</span>reg1[i])<span class="sc">*</span><span class="dv">100</span>)</span>
<span id="cb9-12"><a href="#cb9-12" aria-hidden="true" tabindex="-1"></a>  df[i, <span class="dv">7</span><span class="sc">:</span><span class="dv">8</span>]   <span class="ot">&lt;-</span> <span class="fu">sprintf</span>(<span class="st">&quot;%.1f&quot;</span>,</span>
<span id="cb9-13"><a href="#cb9-13" aria-hidden="true" tabindex="-1"></a>                          PowerTOST<span class="sc">::</span><span class="fu">scABEL</span>(CV[i]<span class="sc">/</span><span class="dv">100</span>,</span>
<span id="cb9-14"><a href="#cb9-14" aria-hidden="true" tabindex="-1"></a>                                            <span class="at">regulator =</span> df<span class="sc">$</span>reg2[i])<span class="sc">*</span><span class="dv">100</span>)</span>
<span id="cb9-15"><a href="#cb9-15" aria-hidden="true" tabindex="-1"></a>  df[i, <span class="dv">11</span><span class="sc">:</span><span class="dv">12</span>] <span class="ot">&lt;-</span> <span class="fu">sprintf</span>(<span class="st">&quot;%.3f&quot;</span>,</span>
<span id="cb9-16"><a href="#cb9-16" aria-hidden="true" tabindex="-1"></a>                          PowerTOST<span class="sc">::</span><span class="fu">scABEL</span>(CV[i]<span class="sc">/</span><span class="dv">100</span>,</span>
<span id="cb9-17"><a href="#cb9-17" aria-hidden="true" tabindex="-1"></a>                                            <span class="at">regulator =</span> df<span class="sc">$</span>reg3[i])<span class="sc">*</span><span class="dv">100</span>)</span>
<span id="cb9-18"><a href="#cb9-18" aria-hidden="true" tabindex="-1"></a>}</span>
<span id="cb9-19"><a href="#cb9-19" aria-hidden="true" tabindex="-1"></a>df<span class="sc">$</span>cap3[df<span class="sc">$</span>CV <span class="sc">&lt;=</span> <span class="dv">30</span>] <span class="ot">&lt;-</span> df<span class="sc">$</span>cap2[df<span class="sc">$</span>CV <span class="sc">&lt;=</span> <span class="dv">30</span>] <span class="ot">&lt;-</span> df<span class="sc">$</span>cap1[df<span class="sc">$</span>CV <span class="sc">&lt;=</span> <span class="dv">30</span>] <span class="ot">&lt;-</span> <span class="st">&quot;lower&quot;</span></span>
<span id="cb9-20"><a href="#cb9-20" aria-hidden="true" tabindex="-1"></a>df<span class="sc">$</span>cap1[df<span class="sc">$</span>CV <span class="sc">&gt;=</span> <span class="dv">50</span> <span class="sc">&amp;</span> df<span class="sc">$</span>reg1 <span class="sc">==</span> <span class="st">&quot;EMA&quot;</span>]    <span class="ot">&lt;-</span> <span class="st">&quot;upper&quot;</span></span>
<span id="cb9-21"><a href="#cb9-21" aria-hidden="true" tabindex="-1"></a>df<span class="sc">$</span>cap2[df<span class="sc">$</span>CV <span class="sc">&gt;=</span> <span class="fl">57.382</span> <span class="sc">&amp;</span> df<span class="sc">$</span>reg2 <span class="sc">==</span> <span class="st">&quot;HC&quot;</span>] <span class="ot">&lt;-</span> <span class="st">&quot;upper&quot;</span></span>
<span id="cb9-22"><a href="#cb9-22" aria-hidden="true" tabindex="-1"></a><span class="fu">names</span>(df) <span class="ot">&lt;-</span> <span class="fu">c</span>(<span class="st">&quot;CV(%)&quot;</span>, <span class="fu">rep</span>(<span class="fu">c</span>(<span class="st">&quot;reg&quot;</span>, <span class="st">&quot;L(%)&quot;</span>, <span class="st">&quot;U(%)&quot;</span>, <span class="st">&quot;cap&quot;</span>), <span class="dv">3</span>))</span>
<span id="cb9-23"><a href="#cb9-23" aria-hidden="true" tabindex="-1"></a><span class="fu">print</span>(df, <span class="at">row.names =</span> <span class="cn">FALSE</span>)</span>
<span id="cb9-24"><a href="#cb9-24" aria-hidden="true" tabindex="-1"></a><span class="co">#   CV(%) reg   L(%)    U(%)   cap reg L(%)  U(%)   cap reg   L(%)    U(%)   cap</span></span>
<span id="cb9-25"><a href="#cb9-25" aria-hidden="true" tabindex="-1"></a><span class="co">#  30.000 EMA 80.000 125.000 lower  HC 80.0 125.0 lower GCC 80.000 125.000 lower</span></span>
<span id="cb9-26"><a href="#cb9-26" aria-hidden="true" tabindex="-1"></a><span class="co">#  50.000 EMA 69.837 143.191 upper  HC 69.8 143.2       GCC 75.000 133.333      </span></span>
<span id="cb9-27"><a href="#cb9-27" aria-hidden="true" tabindex="-1"></a><span class="co">#  57.382 EMA 69.837 143.191 upper  HC 66.7 150.0 upper GCC 75.000 133.333</span></span></code></pre></div>
<div class="figure">
<img src="data:image/png;base64,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" width="560" alt />
<p class="caption">Discrete limits resulting from rounding (EMA)</p>
</div>
</div>
<div id="df_comp" class="section level2">
<h2>Degrees of freedom, comparison of methods</h2>
<p>The SAS code provided by the
<abbr title="European Medicines Agency">EMA</abbr> in the
<abbr title="Questions &amp; Answers">Q&amp;A</abbr> document does not
specify how the degrees of freedom should be calculated in Method B.
Hence, the default in <code>PROC MIXED</code>, namely
<code>DDFM=CONTAIN</code> is applied, <em>i.e.</em>,
<code>method.B(..., option = 2</code>). For incomplete data (missing
periods) Satterthwaite’s approximation of the degrees of freedom,
<em>i.e.</em>, <code>method.B(..., option = 1)</code> or Kenward-Roger
<code>method.B(..., option = 3)</code> might be a better choice – if
stated as such in the
<abbr title="Statistical Analysis Plan">SAP</abbr>.<br />
For background about approximations in different software packages see
the electronic <a href="https://static-content.springer.com/esm/art%3A10.1208%2Fs12248-020-0427-6/MediaObjects/12248_2020_427_MOESM1_ESM.docx">Supplementary
Material</a> of Schütz <em>et al.</em></p>
<p>The <abbr title="European Medicines Agency">EMA</abbr> seemingly
prefers Method A:</p>
<blockquote>
<p><em>A simple linear mixed model, which assumes identical
within-subject variability (Method B), may be acceptable as long as
results obtained with the two methods do not lead to different
regulatory decisions. However, in borderline cases […] additional
analysis using Method A might be required.</em></p>
<p>— <abbr title="Questions &amp; Answers">Q&amp;A</abbr> document (January
2011 and later revisions)</p>
</blockquote>
<p>The half-width of the confidence interval in log-scale allows a
comparison of methods (B <em>v.s.</em> A) where a higher value
<em>might</em> point towards a more conservative decision.<a href="#fn18" class="footnote-ref" id="fnref18"><sup>18</sup></a> In the
provided example datasets – with one exception – the conclusion of
<abbr title="Bioequivalence">BE</abbr> (based on the mixed criterion)
agrees between Method A and Method B.<br />
However, for the highly incomplete dataset 14 Method A is
<em>liberal</em> (passing by
<abbr title="Analysis of Variance">ANOVA</abbr> but failing by the
random effects model):</p>
<div class="sourceCode" id="cb10"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb10-1"><a href="#cb10-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Compare Method B acc. to the GL with Method A for all reference data sets.</span></span>
<span id="cb10-2"><a href="#cb10-2" aria-hidden="true" tabindex="-1"></a>ds <span class="ot">&lt;-</span> <span class="fu">substr</span>(<span class="fu">grep</span>(<span class="st">&quot;rds&quot;</span>, <span class="fu">unname</span>(<span class="fu">unlist</span>(<span class="fu">data</span>(<span class="at">package =</span> <span class="st">&quot;replicateBE&quot;</span>))),</span>
<span id="cb10-3"><a href="#cb10-3" aria-hidden="true" tabindex="-1"></a>                  <span class="at">value =</span> <span class="cn">TRUE</span>), <span class="at">start =</span> <span class="dv">1</span>, <span class="at">stop =</span> <span class="dv">5</span>)</span>
<span id="cb10-4"><a href="#cb10-4" aria-hidden="true" tabindex="-1"></a><span class="cf">for</span> (i <span class="cf">in</span> <span class="fu">seq_along</span>(ds)) {</span>
<span id="cb10-5"><a href="#cb10-5" aria-hidden="true" tabindex="-1"></a>  A <span class="ot">&lt;-</span> <span class="fu">method.A</span>(<span class="at">print =</span> <span class="cn">FALSE</span>, <span class="at">details =</span> <span class="cn">TRUE</span>, <span class="at">data =</span> <span class="fu">eval</span>(<span class="fu">parse</span>(<span class="at">text =</span> ds[i])))<span class="sc">$</span>BE</span>
<span id="cb10-6"><a href="#cb10-6" aria-hidden="true" tabindex="-1"></a>  B <span class="ot">&lt;-</span> <span class="fu">method.B</span>(<span class="at">print =</span> <span class="cn">FALSE</span>, <span class="at">details =</span> <span class="cn">TRUE</span>, <span class="at">data =</span> <span class="fu">eval</span>(<span class="fu">parse</span>(<span class="at">text =</span> ds[i])))<span class="sc">$</span>BE</span>
<span id="cb10-7"><a href="#cb10-7" aria-hidden="true" tabindex="-1"></a>  r <span class="ot">&lt;-</span> <span class="fu">paste0</span>(<span class="st">&quot;A &quot;</span>, A, <span class="st">&quot;, B &quot;</span>, B, <span class="st">&quot; - &quot;</span>)</span>
<span id="cb10-8"><a href="#cb10-8" aria-hidden="true" tabindex="-1"></a>  <span class="fu">cat</span>(<span class="fu">paste0</span>(ds[i], <span class="st">&quot;:&quot;</span>), r)</span>
<span id="cb10-9"><a href="#cb10-9" aria-hidden="true" tabindex="-1"></a>  <span class="cf">if</span> (A <span class="sc">==</span> B) {</span>
<span id="cb10-10"><a href="#cb10-10" aria-hidden="true" tabindex="-1"></a>    <span class="fu">cat</span>(<span class="st">&quot;Methods agree.</span><span class="sc">\n</span><span class="st">&quot;</span>)</span>
<span id="cb10-11"><a href="#cb10-11" aria-hidden="true" tabindex="-1"></a>  } <span class="cf">else</span> {</span>
<span id="cb10-12"><a href="#cb10-12" aria-hidden="true" tabindex="-1"></a>    <span class="cf">if</span> (A <span class="sc">==</span> <span class="st">&quot;fail&quot;</span> <span class="sc">&amp;</span> B <span class="sc">==</span> <span class="st">&quot;pass&quot;</span>) {</span>
<span id="cb10-13"><a href="#cb10-13" aria-hidden="true" tabindex="-1"></a>      <span class="fu">cat</span>(<span class="st">&quot;Method A is conservative.</span><span class="sc">\n</span><span class="st">&quot;</span>)</span>
<span id="cb10-14"><a href="#cb10-14" aria-hidden="true" tabindex="-1"></a>    } <span class="cf">else</span> {</span>
<span id="cb10-15"><a href="#cb10-15" aria-hidden="true" tabindex="-1"></a>      <span class="fu">cat</span>(<span class="st">&quot;Method B is conservative.</span><span class="sc">\n</span><span class="st">&quot;</span>)</span>
<span id="cb10-16"><a href="#cb10-16" aria-hidden="true" tabindex="-1"></a>    }</span>
<span id="cb10-17"><a href="#cb10-17" aria-hidden="true" tabindex="-1"></a>  }</span>
<span id="cb10-18"><a href="#cb10-18" aria-hidden="true" tabindex="-1"></a>}</span>
<span id="cb10-19"><a href="#cb10-19" aria-hidden="true" tabindex="-1"></a><span class="co"># rds01: A pass, B pass - Methods agree.</span></span>
<span id="cb10-20"><a href="#cb10-20" aria-hidden="true" tabindex="-1"></a><span class="co"># rds02: A pass, B pass - Methods agree.</span></span>
<span id="cb10-21"><a href="#cb10-21" aria-hidden="true" tabindex="-1"></a><span class="co"># rds03: A pass, B pass - Methods agree.</span></span>
<span id="cb10-22"><a href="#cb10-22" aria-hidden="true" tabindex="-1"></a><span class="co"># rds04: A fail, B fail - Methods agree.</span></span>
<span id="cb10-23"><a href="#cb10-23" aria-hidden="true" tabindex="-1"></a><span class="co"># rds05: A pass, B pass - Methods agree.</span></span>
<span id="cb10-24"><a href="#cb10-24" aria-hidden="true" tabindex="-1"></a><span class="co"># rds06: A pass, B pass - Methods agree.</span></span>
<span id="cb10-25"><a href="#cb10-25" aria-hidden="true" tabindex="-1"></a><span class="co"># rds07: A pass, B pass - Methods agree.</span></span>
<span id="cb10-26"><a href="#cb10-26" aria-hidden="true" tabindex="-1"></a><span class="co"># rds08: A pass, B pass - Methods agree.</span></span>
<span id="cb10-27"><a href="#cb10-27" aria-hidden="true" tabindex="-1"></a><span class="co"># rds09: A pass, B pass - Methods agree.</span></span>
<span id="cb10-28"><a href="#cb10-28" aria-hidden="true" tabindex="-1"></a><span class="co"># rds10: A pass, B pass - Methods agree.</span></span>
<span id="cb10-29"><a href="#cb10-29" aria-hidden="true" tabindex="-1"></a><span class="co"># rds11: A pass, B pass - Methods agree.</span></span>
<span id="cb10-30"><a href="#cb10-30" aria-hidden="true" tabindex="-1"></a><span class="co"># rds12: A fail, B fail - Methods agree.</span></span>
<span id="cb10-31"><a href="#cb10-31" aria-hidden="true" tabindex="-1"></a><span class="co"># rds13: A fail, B fail - Methods agree.</span></span>
<span id="cb10-32"><a href="#cb10-32" aria-hidden="true" tabindex="-1"></a><span class="co"># rds14: A pass, B fail - Method B is conservative.</span></span>
<span id="cb10-33"><a href="#cb10-33" aria-hidden="true" tabindex="-1"></a><span class="co"># rds15: A fail, B fail - Methods agree.</span></span>
<span id="cb10-34"><a href="#cb10-34" aria-hidden="true" tabindex="-1"></a><span class="co"># rds16: A fail, B fail - Methods agree.</span></span>
<span id="cb10-35"><a href="#cb10-35" aria-hidden="true" tabindex="-1"></a><span class="co"># rds17: A fail, B fail - Methods agree.</span></span>
<span id="cb10-36"><a href="#cb10-36" aria-hidden="true" tabindex="-1"></a><span class="co"># rds18: A fail, B fail - Methods agree.</span></span>
<span id="cb10-37"><a href="#cb10-37" aria-hidden="true" tabindex="-1"></a><span class="co"># rds19: A fail, B fail - Methods agree.</span></span>
<span id="cb10-38"><a href="#cb10-38" aria-hidden="true" tabindex="-1"></a><span class="co"># rds20: A fail, B fail - Methods agree.</span></span>
<span id="cb10-39"><a href="#cb10-39" aria-hidden="true" tabindex="-1"></a><span class="co"># rds21: A fail, B fail - Methods agree.</span></span>
<span id="cb10-40"><a href="#cb10-40" aria-hidden="true" tabindex="-1"></a><span class="co"># rds22: A pass, B pass - Methods agree.</span></span>
<span id="cb10-41"><a href="#cb10-41" aria-hidden="true" tabindex="-1"></a><span class="co"># rds23: A pass, B pass - Methods agree.</span></span>
<span id="cb10-42"><a href="#cb10-42" aria-hidden="true" tabindex="-1"></a><span class="co"># rds24: A pass, B pass - Methods agree.</span></span>
<span id="cb10-43"><a href="#cb10-43" aria-hidden="true" tabindex="-1"></a><span class="co"># rds25: A pass, B pass - Methods agree.</span></span>
<span id="cb10-44"><a href="#cb10-44" aria-hidden="true" tabindex="-1"></a><span class="co"># rds26: A fail, B fail - Methods agree.</span></span>
<span id="cb10-45"><a href="#cb10-45" aria-hidden="true" tabindex="-1"></a><span class="co"># rds27: A pass, B pass - Methods agree.</span></span>
<span id="cb10-46"><a href="#cb10-46" aria-hidden="true" tabindex="-1"></a><span class="co"># rds28: A pass, B pass - Methods agree.</span></span>
<span id="cb10-47"><a href="#cb10-47" aria-hidden="true" tabindex="-1"></a><span class="co"># rds29: A pass, B pass - Methods agree.</span></span>
<span id="cb10-48"><a href="#cb10-48" aria-hidden="true" tabindex="-1"></a><span class="co"># rds30: A fail, B fail - Methods agree.</span></span></code></pre></div>
<p>Exploring dataset 14:</p>
<div class="sourceCode" id="cb11"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb11-1"><a href="#cb11-1" aria-hidden="true" tabindex="-1"></a>A  <span class="ot">&lt;-</span> <span class="fu">method.A</span>(<span class="at">print =</span> <span class="cn">FALSE</span>, <span class="at">details =</span> <span class="cn">TRUE</span>, <span class="at">data =</span> rds14)</span>
<span id="cb11-2"><a href="#cb11-2" aria-hidden="true" tabindex="-1"></a>B1 <span class="ot">&lt;-</span> <span class="fu">method.B</span>(<span class="at">print =</span> <span class="cn">FALSE</span>, <span class="at">details =</span> <span class="cn">TRUE</span>, <span class="at">data =</span> rds14, <span class="at">option =</span> <span class="dv">1</span>)</span>
<span id="cb11-3"><a href="#cb11-3" aria-hidden="true" tabindex="-1"></a>B2 <span class="ot">&lt;-</span> <span class="fu">method.B</span>(<span class="at">print =</span> <span class="cn">FALSE</span>, <span class="at">details =</span> <span class="cn">TRUE</span>, <span class="at">data =</span> rds14) <span class="co"># apply default option</span></span>
<span id="cb11-4"><a href="#cb11-4" aria-hidden="true" tabindex="-1"></a>B3 <span class="ot">&lt;-</span> <span class="fu">method.B</span>(<span class="at">print =</span> <span class="cn">FALSE</span>, <span class="at">details =</span> <span class="cn">TRUE</span>, <span class="at">data =</span> rds14, <span class="at">option =</span> <span class="dv">3</span>)</span>
<span id="cb11-5"><a href="#cb11-5" aria-hidden="true" tabindex="-1"></a><span class="co"># Rounding of CI according to the GL</span></span>
<span id="cb11-6"><a href="#cb11-6" aria-hidden="true" tabindex="-1"></a>A[<span class="dv">17</span><span class="sc">:</span><span class="dv">21</span>]  <span class="ot">&lt;-</span> <span class="fu">round</span>(A[<span class="dv">17</span><span class="sc">:</span><span class="dv">21</span>],  <span class="dv">2</span>) <span class="co"># all effects fixed</span></span>
<span id="cb11-7"><a href="#cb11-7" aria-hidden="true" tabindex="-1"></a>B1[<span class="dv">17</span><span class="sc">:</span><span class="dv">21</span>] <span class="ot">&lt;-</span> <span class="fu">round</span>(B1[<span class="dv">17</span><span class="sc">:</span><span class="dv">21</span>], <span class="dv">2</span>) <span class="co"># Satterthwaite&#39;s df</span></span>
<span id="cb11-8"><a href="#cb11-8" aria-hidden="true" tabindex="-1"></a>B2[<span class="dv">17</span><span class="sc">:</span><span class="dv">21</span>] <span class="ot">&lt;-</span> <span class="fu">round</span>(B2[<span class="dv">17</span><span class="sc">:</span><span class="dv">21</span>], <span class="dv">2</span>) <span class="co"># df acc. to Q&amp;A</span></span>
<span id="cb11-9"><a href="#cb11-9" aria-hidden="true" tabindex="-1"></a>B3[<span class="dv">17</span><span class="sc">:</span><span class="dv">21</span>] <span class="ot">&lt;-</span> <span class="fu">round</span>(B3[<span class="dv">17</span><span class="sc">:</span><span class="dv">21</span>], <span class="dv">2</span>) <span class="co"># Kenward-Roger df</span></span>
<span id="cb11-10"><a href="#cb11-10" aria-hidden="true" tabindex="-1"></a>cs <span class="ot">&lt;-</span> <span class="fu">c</span>(<span class="dv">2</span>, <span class="dv">10</span>, <span class="dv">17</span><span class="sc">:</span><span class="dv">25</span>)</span>
<span id="cb11-11"><a href="#cb11-11" aria-hidden="true" tabindex="-1"></a>df <span class="ot">&lt;-</span> <span class="fu">rbind</span>(A[cs], B1[cs], B2[cs], B3[cs])</span>
<span id="cb11-12"><a href="#cb11-12" aria-hidden="true" tabindex="-1"></a><span class="fu">names</span>(df)[<span class="fu">c</span>(<span class="dv">1</span>, <span class="dv">3</span><span class="sc">:</span><span class="dv">6</span>, <span class="dv">11</span>)] <span class="ot">&lt;-</span> <span class="fu">c</span>(<span class="st">&quot;Meth.&quot;</span>, <span class="st">&quot;L(%)&quot;</span>, <span class="st">&quot;U(%)&quot;</span>,</span>
<span id="cb11-13"><a href="#cb11-13" aria-hidden="true" tabindex="-1"></a>                              <span class="st">&quot;CL.lo(%)&quot;</span>, <span class="st">&quot;CL.hi(%)&quot;</span>, <span class="st">&quot;hw&quot;</span>)</span>
<span id="cb11-14"><a href="#cb11-14" aria-hidden="true" tabindex="-1"></a>df[, <span class="fu">c</span>(<span class="dv">2</span>, <span class="dv">11</span>)] <span class="ot">&lt;-</span> <span class="fu">signif</span>(df[, <span class="fu">c</span>(<span class="dv">2</span>, <span class="dv">11</span>)], <span class="dv">5</span>)</span>
<span id="cb11-15"><a href="#cb11-15" aria-hidden="true" tabindex="-1"></a><span class="fu">print</span>(df[<span class="fu">order</span>(df<span class="sc">$</span>hw, df<span class="sc">$</span>BE, <span class="at">decreasing =</span> <span class="fu">c</span>(<span class="cn">FALSE</span>, <span class="cn">TRUE</span>),</span>
<span id="cb11-16"><a href="#cb11-16" aria-hidden="true" tabindex="-1"></a>               <span class="at">method =</span> <span class="st">&quot;radix&quot;</span>), ], <span class="at">row.names =</span> <span class="cn">FALSE</span>)</span>
<span id="cb11-17"><a href="#cb11-17" aria-hidden="true" tabindex="-1"></a><span class="co">#  Meth.     DF  L(%)   U(%) CL.lo(%) CL.hi(%) PE(%)   CI  GMR   BE      hw</span></span>
<span id="cb11-18"><a href="#cb11-18" aria-hidden="true" tabindex="-1"></a><span class="co">#      A 197.44 69.84 143.19    69.21   121.27 91.62 fail pass fail 0.28043</span></span>
<span id="cb11-19"><a href="#cb11-19" aria-hidden="true" tabindex="-1"></a><span class="co">#      A 192.00 69.84 143.19    69.21   121.28 91.62 fail pass fail 0.28046</span></span>
<span id="cb11-20"><a href="#cb11-20" aria-hidden="true" tabindex="-1"></a><span class="co">#      A 195.99 69.84 143.19    69.21   121.28 91.62 fail pass fail 0.28052</span></span>
<span id="cb11-21"><a href="#cb11-21" aria-hidden="true" tabindex="-1"></a><span class="co">#      A 192.00 69.84 143.19    69.99   123.17 92.85 pass pass pass 0.28261</span></span></code></pre></div>
<p>All variants of Method B are more conservative than Method A. Before
rounding the confidence interval, <code>option = 2</code> with 192
degrees of freedom would be more conservative (lower
<abbr title="Confidence Limit">CL</abbr> 69.21029) than
<code>option = 1</code> with 197.44 degrees of freedom (lower
<abbr title="Confidence Limit">CL</abbr> 69.21286). Given the
incompleteness of this data set (four missings in period 2, twelve in
period 3, and 19 in period 4), Satterthwaite’s or Kenward-Roger degrees
of freedom are probably the better choice.</p>
<p>For detailed comparisons between methods based on simulations see the
electronic <a href="https://static-content.springer.com/esm/art%3A10.1208%2Fs12248-020-0427-6/MediaObjects/12248_2020_427_MOESM1_ESM.docx">Supplementary
Material</a> of Schütz <em>et al.</em></p>
</div>
<div id="ola" class="section level2">
<h2>Outlier analysis</h2>
<p>It is an open issue how outliers should be handled.</p>
<blockquote>
<p><em>The applicant should justify that the calculated intra-subject
variability is a reliable estimate and that it is not the result of
outliers.</em></p>
<p>— CHMP Bioequivalence Guideline</p>
</blockquote>
<p>The author ‘suggested’ box plots as a mere joke [<em>sic</em>] at the
<abbr title="European Generic Medicines Association">EGA</abbr>/<abbr title="European Medicines Agency">EMA</abbr>
symposium, being aware of their non­para­metric nature and the
<abbr title="European Medicines Agency">EMA</abbr>’s reluctance towards
robust methods. Alas, this <em>joke</em> was included in the
<abbr title="Questions &amp; Answers">Q&amp;A</abbr> document.</p>
<blockquote>
<p><em>[…] a study could be acceptable if the bioequivalence
requirements are met both including the outlier subject (using the
scaled average bioequivalence approach and the within-subject CV with
this subject) and after exclusion of the outlier (using the
within-subject CV without this subject).</em></p>
<p><em>An outlier test is not an expectation of the medicines agencies
but outliers could be shown by a box plot. This would allow the
medicines agencies to compare the data between them.</em></p>
<p>— EGA/EMA Q&amp;A document</p>
</blockquote>
<p>With the additional argument <code>ola = TRUE</code> in
<code>method.A()</code> and <code>method.B()</code> an outlier analysis
is performed, where the default <code>fence = 2</code>.<a href="#fn19" class="footnote-ref" id="fnref19"><sup>19</sup></a></p>
<p>Results differ slightly depending on software’s algorithms to
calculate the median and quartiles. Example with the nine types
implemented in R:</p>
<div class="sourceCode" id="cb12"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb12-1"><a href="#cb12-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Compare different types with some random data</span></span>
<span id="cb12-2"><a href="#cb12-2" aria-hidden="true" tabindex="-1"></a><span class="fu">set.seed</span>(<span class="dv">123456</span>)</span>
<span id="cb12-3"><a href="#cb12-3" aria-hidden="true" tabindex="-1"></a>x <span class="ot">&lt;-</span> <span class="fu">rnorm</span>(<span class="dv">48</span>)</span>
<span id="cb12-4"><a href="#cb12-4" aria-hidden="true" tabindex="-1"></a>p <span class="ot">&lt;-</span> <span class="fu">c</span>(<span class="dv">25</span>, <span class="dv">50</span>, <span class="dv">75</span>)<span class="sc">/</span><span class="dv">100</span></span>
<span id="cb12-5"><a href="#cb12-5" aria-hidden="true" tabindex="-1"></a>q <span class="ot">&lt;-</span> <span class="fu">matrix</span>(<span class="at">data =</span> <span class="st">&quot;&quot;</span>, <span class="at">nrow =</span> <span class="dv">9</span>, <span class="at">ncol =</span> <span class="dv">4</span>,</span>
<span id="cb12-6"><a href="#cb12-6" aria-hidden="true" tabindex="-1"></a>            <span class="at">dimnames =</span> <span class="fu">list</span>(<span class="fu">paste</span>(<span class="st">&quot;type =&quot;</span>, <span class="dv">1</span><span class="sc">:</span><span class="dv">9</span>),</span>
<span id="cb12-7"><a href="#cb12-7" aria-hidden="true" tabindex="-1"></a>                            <span class="fu">c</span>(<span class="st">&quot;1st quart.&quot;</span>, <span class="st">&quot;median&quot;</span>, <span class="st">&quot;3rd quart.&quot;</span>,</span>
<span id="cb12-8"><a href="#cb12-8" aria-hidden="true" tabindex="-1"></a>                              <span class="st">&quot;software / default&quot;</span>)))</span>
<span id="cb12-9"><a href="#cb12-9" aria-hidden="true" tabindex="-1"></a><span class="cf">for</span> (i <span class="cf">in</span> <span class="dv">1</span><span class="sc">:</span><span class="dv">9</span>) {</span>
<span id="cb12-10"><a href="#cb12-10" aria-hidden="true" tabindex="-1"></a>  q[i, <span class="dv">1</span><span class="sc">:</span><span class="dv">3</span>] <span class="ot">&lt;-</span> <span class="fu">sprintf</span>(<span class="st">&quot;%.5f&quot;</span>, <span class="fu">quantile</span>(x, <span class="at">prob =</span> p, <span class="at">type =</span> i))</span>
<span id="cb12-11"><a href="#cb12-11" aria-hidden="true" tabindex="-1"></a>}</span>
<span id="cb12-12"><a href="#cb12-12" aria-hidden="true" tabindex="-1"></a>q[<span class="fu">c</span>(<span class="dv">2</span>, <span class="dv">4</span>, <span class="dv">6</span><span class="sc">:</span><span class="dv">8</span>), <span class="dv">4</span>] <span class="ot">&lt;-</span> <span class="fu">c</span>(<span class="st">&quot;SAS, Stata&quot;</span>, <span class="st">&quot;SciPy&quot;</span>, <span class="st">&quot;Phoenix, Minitab, SPSS&quot;</span>,</span>
<span id="cb12-13"><a href="#cb12-13" aria-hidden="true" tabindex="-1"></a>                        <span class="st">&quot;R, S, MATLAB, Octave, Excel&quot;</span>, <span class="st">&quot;Maple&quot;</span>)</span>
<span id="cb12-14"><a href="#cb12-14" aria-hidden="true" tabindex="-1"></a><span class="fu">print</span>(<span class="fu">as.data.frame</span>(q))</span>
<span id="cb12-15"><a href="#cb12-15" aria-hidden="true" tabindex="-1"></a><span class="co">#          1st quart.  median 3rd quart.          software / default</span></span>
<span id="cb12-16"><a href="#cb12-16" aria-hidden="true" tabindex="-1"></a><span class="co"># type = 1   -0.75397 0.05761    0.96782                            </span></span>
<span id="cb12-17"><a href="#cb12-17" aria-hidden="true" tabindex="-1"></a><span class="co"># type = 2   -0.74451 0.06358    0.96984                  SAS, Stata</span></span>
<span id="cb12-18"><a href="#cb12-18" aria-hidden="true" tabindex="-1"></a><span class="co"># type = 3   -0.75397 0.05761    0.96782                            </span></span>
<span id="cb12-19"><a href="#cb12-19" aria-hidden="true" tabindex="-1"></a><span class="co"># type = 4   -0.75397 0.05761    0.96782                       SciPy</span></span>
<span id="cb12-20"><a href="#cb12-20" aria-hidden="true" tabindex="-1"></a><span class="co"># type = 5   -0.74451 0.06358    0.96984                            </span></span>
<span id="cb12-21"><a href="#cb12-21" aria-hidden="true" tabindex="-1"></a><span class="co"># type = 6   -0.74924 0.06358    0.97084      Phoenix, Minitab, SPSS</span></span>
<span id="cb12-22"><a href="#cb12-22" aria-hidden="true" tabindex="-1"></a><span class="co"># type = 7   -0.73978 0.06358    0.96883 R, S, MATLAB, Octave, Excel</span></span>
<span id="cb12-23"><a href="#cb12-23" aria-hidden="true" tabindex="-1"></a><span class="co"># type = 8   -0.74609 0.06358    0.97017                       Maple</span></span>
<span id="cb12-24"><a href="#cb12-24" aria-hidden="true" tabindex="-1"></a><span class="co"># type = 9   -0.74569 0.06358    0.97009</span></span></code></pre></div>
<p>Note the differences even in the medians.</p>
<ul>
<li>Box plots of studentized<a href="#fn20" class="footnote-ref" id="fnref20"><sup>20</sup></a> and standarized<a href="#fn21" class="footnote-ref" id="fnref21"><sup>21</sup></a> model residuals are
constructed.<a href="#fn22" class="footnote-ref" id="fnref22"><sup>22</sup></a></li>
<li>Potential outliers are flagged based on the argument
<code>fence</code> provided by the user.</li>
<li>With the additional argument <code>verbose = TRUE</code> detailed
information is shown in the console.</li>
</ul>
<p>Example for the reference dataset 01:</p>
<pre><code>Outlier analysis
 (externally) studentized residuals
 Limits (2×IQR whiskers): -1.717435, 1.877877
 Outliers:
 subject sequence  stud.res
      45     RTRT -6.656940
      52     RTRT  3.453122

 standarized (internally studentized) residuals
 Limits (2×IQR whiskers): -1.69433, 1.845333
 Outliers:
 subject sequence stand.res
      45     RTRT -5.246293
      52     RTRT  3.214663</code></pre>
<p>If based on <em>studentized</em> residuals outliers are detected,
additionally to the expanded limits based on the complete reference
data, tighter limits are calculated based on <em>CV</em><sub>wR</sub>
after exclusion of outliers and <abbr title="Bioequivalence">BE</abbr>
assessed with the new limits. Note that <em>standardized</em> residuals
are given for informational purposes only and <em>not</em> used for
exclusion of outliers.</p>
<p>Output for the reference dataset 01 (re-ordered for clarity):</p>
<pre><code>CVwR               :  46.96% (reference-scaling applicable)
swR                :   0.44645
Expanded limits    :  71.23% ... 140.40% [100exp(±0.760·swR)]
Assessment based on original CVwR 46.96%
────────────────────────────────────────
Confidence interval: 107.11% ... 124.89%  pass
Point estimate     : 115.66%              pass
Mixed (CI &amp; PE)    :                      pass
 ╟────────┼─────────────────────┼───────■────────◊─────────■───────────────╢

Outlier fence      :  2×IQR of studentized residuals.
Recalculation due to presence of 2 outliers (subj. 45|52)
─────────────────────────────────────────────────────────
CVwR (outl. excl.) :  32.16% (reference-scaling applicable)
swR (recalculated) :   0.31374
Expanded limits    :  78.79% ... 126.93% [100exp(±0.760·swR)]
Assessment based on recalculated CVwR 32.16%
────────────────────────────────────────────
Confidence interval: pass
Point estimate     : pass
Mixed (CI &amp; PE)    : pass
         ╟┼─────────────────────┼───────■────────◊─────────■─╢</code></pre>
<p>Note that the <abbr title="Point Estimate">PE</abbr> and its
<abbr title="Confidence Interval">CI</abbr> are not affected since the
entire data are used and therefore, these values not reported in the
second analysis (only the conclusion of the assessment).<br />
The ‘ASCII line plot’ is given for informational purposes since its
resolution is only ~0.5%. The filled squares <code>■</code> are the
lower and upper 90% confidence limits, the rhombus <code>◊</code> the
point estimate, the vertical lines <code>│</code> at 100% and the
<abbr title="Point Estimate">PE</abbr> restriction (80.00 – 125.00%),
and the double vertical lines <code>║</code> the expanded limits. The
<abbr title="Point Estimate">PE</abbr> and
<abbr title="Confidence Interval">CI</abbr> take pre­se­dence over other
symbols. In this case the upper limit of the
<abbr title="Point Estimate">PE</abbr> restriction is not visible.<br />
Since both analyses arrive at the same conclusion, the study should be
acceptable according to the
<abbr title="Questions &amp; Answers">Q&amp;A</abbr> document.</p>
<p>An assessment of outliers is <em>not</em> required for Brazil’s
ANVISA.</p>
<p>Health Canada<a href="#fn23" class="footnote-ref" id="fnref23"><sup>23</sup></a> accepts exclusion of outliers
(irrespective of the treatment) if</p>
<ol style="list-style-type: decimal">
<li>the procedure is stated in the protocol and followed <em>before</em>
the results of the analysis are summarised into confidence intervals
(<em>i.e.</em>, regardless of whether results meet the standard),</li>
<li>no more than 5% of the subjects may be considered to be outliers,
unless there are 20 or fewer subjects, in which case only one subject
may be removed,</li>
<li>it is recommended that a simple outlier test such as a studentised
residual being greater than 3 be used, and</li>
<li>the subject in question should be identified as an outlier for all
parameters, for either the test or reference product, upon which the
bioequivalence decision is to be based.</li>
</ol>
<p>Note that assessing of outliers of the <span style="text-decoration:underline">test treatment</span> is currently not
supported. In order to comply with conditions #1 and #3 use (here for
the internal dataset 01 with a fence narrower than the default):<br />
</p>
<pre><code>B1 &lt;- method.B(ola = TRUE, verbose = TRUE, print = FALSE,
               details = FALSE, fence = 1.5, data = rds01,
               option = 1)</code></pre>
<p>You will get</p>
<pre><code>Outlier analysis
 (externally) studentized residuals
 Limits (1.5×IQR whiskers): -1.631514, 1.553557
 Outliers:
 subject sequence  stud.res
      41     RTRT  1.877877
      45     RTRT -6.656940
      46     TRTR -1.717435
      52     RTRT  3.453122

 standarized (internally studentized) residuals
 Limits (1.5×IQR whiskers): -1.612749, 1.53832
 Outliers:
 subject sequence stand.res
      41     RTRT  1.845333
      45     RTRT -5.246293
      46     TRTR -1.694330
      52     RTRT  3.214663</code></pre>
<p>There are 73 subjects in the dataset with two treatments of the
reference. Hence, while observing condition #2, we are allowed to delete
73×5%~3 outliers. Delete subject 45 and 52 with residuals outside ±3
from the dataset. Run the analysis on the reduced dataset as usual.</p>
<p>It must be mentioned that Health Canada’s approach might increase the
Type I Error.<a href="#fn24" class="footnote-ref" id="fnref24"><sup>24</sup></a></p>
</div>
</div>
<div id="app_out" class="section level1">
<h1>Applicability, caveats, outlook</h1>
<p>The <abbr title="European Medicines Agency">EMA</abbr>’s approach of
reference-scaling for highly variable drugs / drug products is currently
recommended in other jurisdictions as well (<em>i.e.</em>, the
<abbr title="World Health Organization">WHO</abbr>; the
<abbr title="Association of Southeast Asian Nations">ASEAN</abbr>,
Australia, Belarus, Brazil, Chile, the East African Community, Egypt,
the <abbr title="Eurasian Economic Union">EEU</abbr>, New Zealand, and
the Russian Federation). Health Canada accepts
<abbr title="Average Bioequivalence with Expanding Limits">ABEL</abbr>
only for <em>AUC</em> with an upper cap of scaling at ~57.4% (maximum
expansion to 66.7 – 150.0%) and <em>might</em> require a true
mixed-effects model. Whether Method B is acceptable is unclear.</p>
<p>If degrees of freedom are approximated (Satterthwaite,
Kenward-Roger), the <abbr title="Statistical Analysis Plan">SAP</abbr>
and statistical report should always specify which method will be / was
used (see <a href="#method.b">above</a>) in order to allow recalculation
in other software. This package uses the <em>expected</em> information
matrix.<a href="#fn25" class="footnote-ref" id="fnref25"><sup>25</sup></a></p>
<p>The estimated <em>CV</em><sub>wR</sub> is always uncertain (the
degree of uncertainty depends on the <em>CV</em><sub>wR</sub> itself,
the design, and – to a minor degree – the sample size), which might lead
to an inflation of the type I error (<em>i.e.</em>, if
<abbr title="Average Bioequivalence with Expanding Limits">ABEL</abbr>
is falsely applied although the <em>true</em> – but unknown –
<em>CV</em><sub>wR</sub> is lower than its estimate).<a href="#fn26" class="footnote-ref" id="fnref26"><sup>26</sup></a><sup>,</sup> <a href="#fn27" class="footnote-ref" id="fnref27"><sup>27</sup></a><br />
Use the optional argument <code>method.A(..., adjust = TRUE)</code> to
iteratively adjust <span class="math inline">\(\small{\alpha}\)</span>
to control the type I error.<a href="#fn28" class="footnote-ref" id="fnref28"><sup>28</sup></a><br />
If you want to apply the most conservative approach of Molins <em>et
al.</em><a href="#fn29" class="footnote-ref" id="fnref29"><sup>29</sup></a> (which corrects for
<em>CV</em><sub>wR</sub> 30% instead of the observed one), get the data
frame of results with<br />
<code>  x &lt;- method.A(..., details = TRUE, print = FALSE)</code>.<br />
Adjust <span class="math inline">\(\small{\alpha}\)</span> in package <a href="https://cran.r-project.org/package=PowerTOST">PowerTOST</a> and
call <code>method.A()</code> again:<br />
<code>  design &lt;- &quot;2x2x4&quot; # your design</code><br />
<code>  n      &lt;- as.integer(strsplit(x[[6]], &quot;|&quot;, fixed = TRUE)[[1]]) # subjects / sequence</code><br />
<code>  y      &lt;- PowerTOST::scABEL.ad(CV = 0.3, n = n, design = design, print = FALSE)</code><br />
<code>  method.A(..., alpha = y$alpha.adj)</code></p>
<p>In a pilot phase the
<abbr title="World Health Organization">WHO</abbr> accepted
reference-scaling for <em>AUC</em> (four period full replicate studies
were mandatory in order to assess the vari­ability associated with each
product).<a href="#fn30" class="footnote-ref" id="fnref30"><sup>30</sup></a> It was not evident how this assessment
should have been done.<br />
In <abbr title="Population Bioequivalence">PBE</abbr> and
<abbr title="Individual Bioequivalence">IBE</abbr> the
<em>s</em><sub>wT</sub>/<em>s</em><sub>wR</sub> ratio was assessed and
‘similar’ variability concluded for a ratio within 0.667 – 1.500.
However, the power of comparing variabilities in a study designed to
compare means is low. This was one of the reasons why
<abbr title="Population Bioequivalence">PBE</abbr> and
<abbr title="Individual Bioequivalence">IBE</abbr> were not implemented
in regulatory practice. An alternative approach is given by the
<abbr title="U.S. Food and Drug Administration">FDA</abbr> where
variabilities are considered ‘comparable’ if the upper confidence limit
of <em>σ</em><sub>wT</sub>/<em>σ</em><sub>wR</sub> is ≤2.5.<a href="#fn31" class="footnote-ref" id="fnref31"><sup>31</sup></a><br />
However, in 2021 the requirement of comparing variabilities was lifted
by the WHO.<a href="#fn32" class="footnote-ref" id="fnref32"><sup>32</sup></a></p>
</div>
<div id="cross" class="section level1">
<h1>Cross-validation</h1>
<p>Results of all reference datasets agree with ones obtained in SAS
(9.4), Phoenix WinNonlin (6.4–8.3.4), STATISTICA (13), SPSS (22.0),
Stata (15.0), and JMP (10.0.2).</p>
</div>
<div id="contr" class="section level1">
<h1>Contributors</h1>
<ul>
<li>Helmut Schütz (Author)</li>
<li>Michael Tomashevskiy (Contributor)</li>
<li>Detlew Labes (Contributor)</li>
</ul>
</div>
<div id="license" class="section level1">
<h1>License</h1>
<p><a href="https://cran.r-project.org/web/licenses/GPL-3" title="GNU General Public License, Version 3">GPL-3</a> Helmut Schütz
2022-05-02</p>
</div>
<div id="disclaimer" class="section level1">
<h1>Disclaimer</h1>
<p>Program offered for Use without any Guarantees and Absolutely No
Warranty. No Liability is accepted for any Loss and Risk to Public
Health Resulting from Use of this R-Code.</p>
</div>
<div class="footnotes footnotes-end-of-document">
<hr />
<ol>
<li id="fn1"><p>Schütz H, Tomashevskiy M, Labes D, Shitova A,
González-de la Parra M, Fuglsang A. <em>Reference Data­sets for Studies
in a Replicate Design Intended for Average Bioequivalence with Expanding
Limits.</em> AAPS J. 2020; 22(2): Article 44. <a href="https://doi.org/10.1208/s12248-020-0427-6">doi:10.1208/s12248-020-0427-6</a>.<a href="#fnref1" class="footnote-back">↩︎</a></p></li>
<li id="fn2"><p>European Medicines Agency. EMA/582648/2016 <a href="https://www.ema.europa.eu/en/documents/other/31-annex-i-statistical-analysis-methods-compatible-ema-bioequivalence-guideline_en.pdf"><em>Annex
I.</em></a> London. 21 September 2016.<a href="#fnref2" class="footnote-back">↩︎</a></p></li>
<li id="fn3"><p>European Medicines Agency. Committee for Medicinal
Products for Human Use. <em>Guideline on the Investigation of
Bioequivalence.</em> <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf">CPMP/EWP/QWP/1401/98
Rev. 1/Corr **</a>. London. 20 January 2010.<a href="#fnref3" class="footnote-back">↩︎</a></p></li>
<li id="fn4"><p>Health Canada. <a href="https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/bioavailability-bioequivalence/conduct-analysis-comparative.pdf">Guidance
Document. Conduct and Analysis of Comparative Bioavailability
Studies.</a> Ottawa. 2018/06/08.<a href="#fnref4" class="footnote-back">↩︎</a></p></li>
<li id="fn5"><p>Executive Board of the Health Ministers’ Council for GCC
States. <em>The GCC Guidelines for Bioequivalence.</em> <a href="https://www.sfda.gov.sa/sites/default/files/2021-10/GCC_Guidelines_Bioequivalence.pdf">Version
3.0</a>. May 2021.<a href="#fnref5" class="footnote-back">↩︎</a></p></li>
<li id="fn6"><p>European Generic Medicines Association. <em>Revised EMA
Bioequivalence Guideline. <a href="https://www.medicinesforeurope.com/wp-content/uploads/2016/03/EGA_BEQ_QA_WEB_QA_1_32.pdf">Questions
&amp; Answers.</a></em> 3<sup>rd</sup> EGA Symposium on Bioequivalence.
London. 1 June 2010.<a href="#fnref6" class="footnote-back">↩︎</a></p></li>
<li id="fn7"><p>Satterthwaite FE. <em>An Approximate Distribution of
Estimates of Variance Components.</em> Biometr Bull. 1946; 2(6): 110–4.
<a href="https://doi.org/10.2307/3002019">doi:10.2307/3002019</a>.<a href="#fnref7" class="footnote-back">↩︎</a></p></li>
<li id="fn8"><p>Kenward MG, Roger JH. <em>Small Sample Inference for
Fixed Effects from Restricted Maximum Likelihood.</em> Biometrics. 1997;
53(3): 983–97. <a href="https://doi.org/10.2307/2533558">doi:10.2307/2533558</a>.<a href="#fnref8" class="footnote-back">↩︎</a></p></li>
<li id="fn9"><p>Kackar RN, Harville DA. <em>Approximations for Standard
Errors of Estimators of Fixed and Random Effects in Mixed Linear
Models.</em> J Am Stat Assoc. 1984; 79(388): 853–62. <a href="https://doi.org/10.1080/01621459.1984.10477102">doi:10.1080/01621459.1984.10477102</a>.<a href="#fnref9" class="footnote-back">↩︎</a></p></li>
<li id="fn10"><p>Medicines Control Council. Registration of Medicines.
<a href="https://www.sahpra.org.za/wp-content/uploads/2020/01/61de452d2.06_Biostudies_Jun15_v6.pdf"><em>Biostudies.</em></a>
Pretoria. June 2015.<a href="#fnref10" class="footnote-back">↩︎</a></p></li>
<li id="fn11"><p>Balaam LN. <em>A Two-Period Design with t<sup>2</sup>
Experimental Units.</em> Biometrics. 1968; 24(1): 61–73. <a href="https://doi.org/10.2307/2528460">doi:10.2307/2528460</a>.<a href="#fnref11" class="footnote-back">↩︎</a></p></li>
<li id="fn12"><p>Chow, SC, Shao J, Wang H. <em>Individual bioequivalence
testing under 2×3 designs.</em> Stat Med. 2002; 21(5): 629–48. <a href="https://doi.org/10.1002/sim.1056">doi:10.1002/sim.1056</a>.<a href="#fnref12" class="footnote-back">↩︎</a></p></li>
<li id="fn13"><p>Napierian logarithm (base <em>e</em>). The decadic
logarithm (base 10) is not supported).<a href="#fnref13" class="footnote-back">↩︎</a></p></li>
<li id="fn14"><p>European Medicines Agency. <em>Questions &amp; Answers:
positions on specific questions addressed to the Pharmacokinetics
Working Party (PKWP).</em> <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-positions-specific-questions-addressed-pharmacokinetics-working-party_en.pdf">EMA/618604/2008</a>.
London. June 2015 (and later revisons).<a href="#fnref14" class="footnote-back">↩︎</a></p></li>
<li id="fn15"><p>Chow S-C, Liu J-p. <em>Design and Analysis of
Bioavailability and Bioequivalence Studies.</em> Boca Raton: CRC Press;
3<sup>rd</sup> ed. 2009. Chapter 3.2.<a href="#fnref15" class="footnote-back">↩︎</a></p></li>
<li id="fn16"><p>It contradicts the law of parsimony. Such a nesting is
superfluous since in comparative bioavailability trials subjects are
uniquely coded. If, say, subject <code>1</code> is allocated to sequence
<code>TRTR</code> there is not yet ‘another’ subject <code>1</code>
allocated to sequence <code>RTRT</code>. This explains the many lines in
SAS <code>PROC GML</code> given with <code>.</code> and in Phoenix
WinNonlin as <code>not estimable</code>.<a href="#fnref16" class="footnote-back">↩︎</a></p></li>
<li id="fn17"><p>European Medicines Agency, Committee for Medicinal
Products for Human Use. <em>Guideline on the pharmacokinetic and
clinical evaluation of modified release dosage forms.</em> <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmacokinetic-clinical-evaluation-modified-release-dosage-forms_en.pdf">EMA/CHMP/EWP/280/96.</a>
London. 20 November 2014.<a href="#fnref17" class="footnote-back">↩︎</a></p></li>
<li id="fn18"><p>Of course, only if point estimates are identical.<a href="#fnref18" class="footnote-back">↩︎</a></p></li>
<li id="fn19"><p>The fences are given by the lowest value still within
<em>m</em>×IQR of the lower quartile, and the highest value still within
<em>m</em>×IQR of the upper quartile, where IQR is the interquartile
range (difference between the 3<sup>rd</sup> and 1<sup>st</sup>
quartiles). Values outside fences are considered outliers. Decreasing
the multiplier <em>m</em> to <em>e.g.</em>, 1.5 might result in many
outliers, whereas increasing the multiplier in only a few.<br />
Different methods exist to calculate quartiles (nine ‘types’ are
available in R, where the default is <code>type = 7</code>). R’s default
is used by S, MATLAB, Octave, and Excel. Phoenix WinNonlin, Minitab, and
SPSS use <code>type = 6</code>, ScyPy uses <code>type = 4</code>,
whereas the default in SAS and Stata is <code>type = 2</code> (though
others are available as well).<a href="#fnref19" class="footnote-back">↩︎</a></p></li>
<li id="fn20"><p><em>Externally</em> studentized: <span class="math inline">\(\small{\widehat{\sigma}_{(i)}^2={1 \over
n-m-1}\sum_{\begin{smallmatrix}j = 1\\j \ne i\end{smallmatrix}}^n
\widehat{\varepsilon\,}_j^{\,2}}\)</span><a href="#fnref20" class="footnote-back">↩︎</a></p></li>
<li id="fn21"><p><em>Internally</em> studentized: <span class="math inline">\(\small{\widehat{\sigma}^2={1 \over
n-m}\sum_{j=1}^n \widehat{\varepsilon\,}_j^{\,2}}\)</span><a href="#fnref21" class="footnote-back">↩︎</a></p></li>
<li id="fn22"><p>Both are available in SAS and R, whereas only the
latter in <em>e.g.</em>, Phoenix WinNonlin. In general the former are
slightly more restrictive. Which one will be used has to be stated in
the <abbr title="Statistical Analysis Plan">SAP</abbr>.<a href="#fnref22" class="footnote-back">↩︎</a></p></li>
<li id="fn23"><p>Health Canada. <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/bioavailability-bioequivalence/conduct-analysis-comparative.html#a234"><em>Guidance
Document: Conduct and Analysis of Comparative Bioavailability Studies.
2.3.5. Outlier Consideration.</em></a> Ottawa. 2018/06/08.<a href="#fnref23" class="footnote-back">↩︎</a></p></li>
<li id="fn24"><p>Fuglsang A. <em>Increased Patient’s Risk Associated
with the Canadian Bioequivalence Guidance Due to Outlier Removal.</em>
Ther Innov Reg Sci. 2022; 56: 168–72. <a href="https://doi.org/10.1007/s43441-021-00344-2">doi:10.1007/s43441-021-00344-2</a>.<a href="#fnref24" class="footnote-back">↩︎</a></p></li>
<li id="fn25"><p>For Satterthwaite only available in Phoenix WinNonlin,
SPSS, and Stata; as an option in SAS by <code>SCORING=1</code>. For
Kenward-Roger default option <code>EIM</code> in Stata. The
<em>observed</em> information matrix is the only available in JMP and
default <code>SCORING=0</code> in SAS; option <code>OIM</code> in
Stata.<a href="#fnref25" class="footnote-back">↩︎</a></p></li>
<li id="fn26"><p>Wonnemann M, Frömke C, Koch A. <em>Inflation of the
Type I Error: Investigations on Regulatory Recom­mendations for
Bioequivalence of Highly Variable Drugs.</em> Pharm Res. 2015; 32(1):
135–43. <a href="https://doi.org/10.1007/s11095-014-1450-z">doi:10.1007/s11095-014-1450-z</a>.<a href="#fnref26" class="footnote-back">↩︎</a></p></li>
<li id="fn27"><p>Muñoz J, Alcaide D, Ocaña J. <em>Consumer’s risk in the
EMA and FDA regulatory approaches for bioequivalence in highly variable
drugs.</em> Stat Med. 2016; 35(12): 1933–43. <a href="https://doi.org/10.1002/sim.6834">doi:10.1002/sim.6834</a>.<a href="#fnref27" class="footnote-back">↩︎</a></p></li>
<li id="fn28"><p>Labes D, Schütz H. <em>Inflation of Type I Error in the
Evaluation of Scaled Average Bioequivalence, and a Method for its
Control.</em> Pharm Res. 2016; 33(11): 2805–14. <a href="https://doi.org/10.1007/s11095-016-2006-1">doi:10.1007/s11095-016-2006-1</a>.<a href="#fnref28" class="footnote-back">↩︎</a></p></li>
<li id="fn29"><p>Molins E, Cobo E, Ocaña J. <em>Two-Stage Designs Versus
European Scaled Average Designs in Bioequivalence Studies for Highly
Variable Drugs: Which to Choose?</em> Stat Med. 2017: 36(30); 4777–88.
<a href="https://doi.org/10.1002/sim.7452">doi:10.1002/sim.7452</a>.<a href="#fnref29" class="footnote-back">↩︎</a></p></li>
<li id="fn30"><p>World Health Organization. <a href="https://extranet.who.int/pqweb/sites/default/files/documents/AUC_criteria_November2018.pdf"><em>Application
of reference-scaled criteria for AUC in bioequivalence studies conducted
for submission to PQTm.</em></a> Geneva. 22 November 2018.<a href="#fnref30" class="footnote-back">↩︎</a></p></li>
<li id="fn31"><p>U.S. Food and Drug Administration, Center for Drug
Evaluation and Research. <a href="https://www.fda.gov/media/87219/Download"><em>Draft Guidance for
Industry. Bioequivalence Studies with Pharmacokinetic Endpoints for
Drugs Submitted Under an ANDA.</em></a> August 2021.<a href="#fnref31" class="footnote-back">↩︎</a></p></li>
<li id="fn32"><p>World Health Organization. <a href="https://extranet.who.int/pqweb/sites/default/files/documents/AUC_criteria_July2021.pdf"><em>Application
of reference-scaled criteria for AUC in bioequivalence studies conducted
for submission to PQT/MED.</em></a> Geneva. 02 July 2021.<a href="#fnref32" class="footnote-back">↩︎</a></p></li>
</ol>
</div>



<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
